EP0894143B2 - Vmp-ähnliche sequenzen von pathogener borrelia - Google Patents

Vmp-ähnliche sequenzen von pathogener borrelia Download PDF

Info

Publication number
EP0894143B2
EP0894143B2 EP97914794A EP97914794A EP0894143B2 EP 0894143 B2 EP0894143 B2 EP 0894143B2 EP 97914794 A EP97914794 A EP 97914794A EP 97914794 A EP97914794 A EP 97914794A EP 0894143 B2 EP0894143 B2 EP 0894143B2
Authority
EP
European Patent Office
Prior art keywords
dna
vmp
polypeptide
sequence
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97914794A
Other languages
English (en)
French (fr)
Other versions
EP0894143B1 (de
EP0894143A1 (de
EP0894143A4 (de
Inventor
Steven J. Norris
Jing-Ren Zhang
John M. Hardham
Jerrilyn K. Howell
Alan G. Barbour
George M. Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21753038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0894143(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Texas System filed Critical University of Texas System
Priority to DE69733944T priority Critical patent/DE69733944T3/de
Priority to EP05010338.1A priority patent/EP1589109B1/de
Publication of EP0894143A1 publication Critical patent/EP0894143A1/de
Publication of EP0894143A4 publication Critical patent/EP0894143A4/de
Application granted granted Critical
Publication of EP0894143B1 publication Critical patent/EP0894143B1/de
Publication of EP0894143B2 publication Critical patent/EP0894143B2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
    • G11B7/007—Arrangement of the information on the record carrier, e.g. form of tracks, actual track shape, e.g. wobbled, or cross-section, e.g. v-shaped; Sequential information structures, e.g. sectoring or header formats within a track
    • G11B7/00772—Arrangement of the information on the record carrier, e.g. form of tracks, actual track shape, e.g. wobbled, or cross-section, e.g. v-shaped; Sequential information structures, e.g. sectoring or header formats within a track on record carriers storing information in the form of optical interference patterns, e.g. holograms
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
    • G11B7/12—Heads, e.g. forming of the optical beam spot or modulation of the optical beam
    • G11B7/125—Optical beam sources therefor, e.g. laser control circuitry specially adapted for optical storage devices; Modulators, e.g. means for controlling the size or intensity of optical spots or optical traces
    • G11B7/128—Modulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
    • G11B7/004—Recording, reproducing or erasing methods; Read, write or erase circuits therefor
    • G11B7/0065—Recording, reproducing or erasing by using optical interference patterns, e.g. holograms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the field of molecular biology; in particular, to immunogenic compositions and recombinant VMP-like genes useful for treatment and diagnosis of Lyme disease. Also included are methods for the determination of virulence factors in Lyme disease.
  • Lyme disease is a bacterial infection caused by pathogenic spirochetes of the genus Borrelia.
  • the infection can occur in humans, dogs, deer, mice and other animals, and is transmitted by arthropod vectors, most notably ticks of the genus Ixodes, Borrelia burgdorferi , the most common cause of Lyme disease in North America, was first cultured in 1982.
  • B. garinii and B. afzelii are the most common infectious agents of Lyme disease in Europe, and another species, B. japonicum, has been described in Japan.
  • Lyme disease is often difficult to diagnose because of shared manifestations with other disorders, and it can also be refractory to treatment during late stages of the disease. It is most common in areas such as suburban regions of upstate New York and Connecticut, where large populations of deer and white-footed mice serve as the principal mammalian hosts and reservoirs of infection. Approximately 10,000 cases of Lyme disease in humans are reported per year in the United States, and it is also a significant veterinary problem due to a high infection rate of dogs and other domestic animals in endemic regions.
  • B. burgdorferi the etiologic agent of Lyme disease, is able to persist for years in patients or animals despite the presence of an active immune response (Steer, 1989; Schutzer, 1992).
  • Antigenic variation has been postulated previously as a mechanism whereby B. burgdorferi evades the immune response in the mammalian host (Schwan et al ., 1991; Wilske et al ., 1992).
  • Antigenic variation has been defined as changes in the structure or expression of antigenic proteins that occurs during infection at a frequency greater than the usual mutation rate (Borst and Geaves, 1987; Robertson and Meyer, 1992; Seifert and So, 1988).
  • Relapsing fever is another disease caused by pathogenic Borrelia. It has both epidemic and endemic forms. The epidemic form is caused by B. recurrentis and is transmitted between humans by lice. It was a major source of morbidity and mortality during World War I, but has been rare since then due largely to public health measures.
  • Endemic relapsing fever is an epizootic infection caused by several Borreliae species, including B. hermsii. It occurs sporadically among hunters, spelunkers, and others who come in contact with infected soft-bodied ticks of the genus Ornithidorus . Relapsing fever is characterized by two or more episodes or "relapses" of high bacteremia (up to 10 8 /ml).
  • the first wave of infection is caused by Borreliae expressing a certain Variable Major Protein (VMP) on their surface (e . g . Vmp21).
  • VMP Variable Major Protein
  • the gene encoding this VMP is located at a promoter site in the expression plasmid, whereas over 24 nonexpressed copies of different VMP genes are present on the so-called silent plasmid.
  • the host develops antibodies against the expressed VMP, the organisms of that stereotype are destroyed and the patient improves.
  • a small proportion of organisms have undergone antigenic switching to a different stereotype.
  • Nonreciprocal recombination occurs between the expression plasmid and the silent plasmid, resulting in the insertion of a different VMP gene in the expression site (e.g., Vmp7).
  • the organisms expressing Vmp7 are not affected by the anti-Vmp21 antibodies, and therefore multiply in the host and cause a second episode of the disease. Up to five of these 3-5 day episodes can occur, separated by
  • Lyme disease may be disabling (particularly in its chronic form), and thus there is a need for effective therapeutic and prophylactic treatment.
  • OspD Outer Surface Protein D
  • Other proteins including OspA and OspC, have been considered as vaccine candidates for Lyme disease, including a recombinant OspA vaccine currently in human clinical trials.
  • Other vaccines are in use or undergoing testing in veterinary applications, including vaccination of dogs.
  • animal studies indicate that OspA vaccination may not be effective against all strains of Lyme disease Borreliae.
  • OspA is also not useful for immunodiagnosis, due to weak antibody responses to OspA in Lyme disease patients.
  • Partial and complete DNA sequences have been determined for several recombinant clones containing DNA encoding VMP-like sequences.
  • the identification and characterization of these sequences now allows: (1) identification of the expressed gene(s) in B. burgdorferi ; (2) expression of these gene(s) by a recombinant vector in a host organism such as E. coli ; (3) immunization of laboratory animals with the resulting polypeptide, and determination of protective activity against B. burgdorferi infection; (4) use of antibodies against the expressed protein to identify the reactive polypeptide(s) in B. burgdorferi cells; (5) use of the expressed protein(s) to detect antibody responses in infected humans and animals; (6) determination of the presence, sequence differences, and expression of the VMP-like DNA sequences in other Lyme disease Borreliae.
  • the invention is contemplated to be useful in the immunoprophylaxis, diagnosis, or treatment of Lyme disease, relapsing fever, or related diseases in humans or animals. It is expected that recombinant or native proteins expressed by the VMP-like genes (or portions thereof) will be useful for (a) immunoprophylaxis against Lyme disease, relapsing fever, or related disorders in humans and animals; (b) immunotherapy of existing Lyme disease, relapsing fever, or related illnesses, by way of immunization of injection of antibodies directed against VMP-like proteins; and (c) immunodiagnosis of Lyme disease, relapsing fever, or related diseases, including their use in kits in which the VMP-like proteins are the sole antigen or one of multiple antigens.
  • the DNA may be employed in: (a) production of recombinant DNA plasmids or other vectors capable of expressing recombinant polypeptides; and (b) design and implementation of nucleic acid probes or oligonucleotides for detection and/or amplification of VMP-like sequences. The latter is expected to have application in the diagnosis of infection with Borrelial organisms.
  • VMP-like sequences such as those contained in pJRZS3-31 have a low degree of homology with OspC from some Lyme disease organisms (e.g. B. burgdorferi 2591), as indicated by a BLASTP homology score of 60 and a probability of 0.0013.
  • B. burgdorferi VMP-like DNA sequences are unique, although they have an apparent evolutionary relationship with other Borrelia genes.
  • Another aspect of the invention is the method for identification of possible virulence factors.
  • This approach entails subtractive hybridization of target DNA from high infectivity organisms with driver DNA from low-infectivity strains or clones. This procedure greatly enriches for sequences which differ between the high- and low-infectivity strains and thus may encode proteins important in virulence.
  • Of particular utility is the use of closely related isogenic clones that differ in their infectivity; in this case, the DNA differences should be restricted more stringently to those related to infectivity.
  • said nucleic acid segments is of 2,000, 5,000 or 8,000 bases in length.
  • Another embodiment is an isolated immunogenic polypeptide having at least 85% homology to the amino acid sequence of SEQ ID NO:2 which specifically binds with antibodies raised against a polypeptide having at least the amino acid sequence of SEQ ID NO:2.
  • Still another embodiment is an antibody that specifically binds to an immunogenic polypeptide encoded by a nucleic acid of the invention, which is able to specifically bind to antibodies raised against a polypeptide having at least the amino acid sequence of SEQ ID NO: 2.
  • the antibody is linked to a detectable label.
  • Another embodiment is an isolated immunogenic polypeptide encoded by a nyucleic acid according to any one of any of the above embodiments.
  • the polypeptide is further defined as an isolated polypeptide which specifically binds with antibodies raised against a polypeptide having at least the amino acid sequence of SEQ ID NO:2.
  • compositions comprising the polypeptide of the above embodiments.
  • the composition is further defined as comprised in a physiologically acceptable excipient.
  • such a composition of any of the above embodiments is for use in a method of generating an immune response comprising a pharmaceutical composition comprising an immunologically effective amount of said composition, wherein the composition is suitable for being administered to a subject.
  • a method for assaying for Borellia infection using the antibodies of the invention to identify Borellia infection by immunogenic binding to a polypeptide obtained from a subject's sample and a method for diagnosing Lyme disease comprising identifying a nucleic acid, a polypeptide or an antibody of the invention in a clinical sample are embodiments of the invention as well as a corresponding kit as claimed.
  • VMP-like protein preparations may be administered in several ways, either locally or systematically in pharmaceutically acceptable formulations. Amounts appropriate for administration are determined on an individual basis depending on such factors as age and sex of the subject, as well as physical condition and weight. Such determinations are well within the skill of the practitioner in the medical field.
  • Modes of administration may include injection of Borrelia VMP-like DNAs into vaccine recipients (human or animal) driven by an appropriate promoter such as CMV, (so called DNA vaccines). Such preparations are for injection directly into lesions or transplanted into patients for systemic immunization. DNA vaccinations techniques are currently well past the initial development stage and have shown promise as vaccination strategies.
  • Recombinant proteins and polypeptides encoded by isolated DNA segments and genes are often referred to with the prefix "r" for recombinant.
  • Isolation of the DNA encoding VMP polypeptides allows one to use methods well known to those of skill in the art and as herein described to make changes in the codons for specific amino acids such that the codons are "preferred usage" codons for a given species.
  • preferred codons will vary significantly for bacterial species as compared with mammalian species; however, there are preferences even among related species. Shown below is a preferred codon usage table human.
  • Isolation of spirochete DNA encoding VMP will allow substitutions for preferred human codons, although expressed polypeptide product from human DNA is expected to be homologous to bacterial VMP and so would be expected to be structurally and functionally equivalent to VMP isolated from a spirochete.
  • VMP-like gene is a gene that hybridizes, under relatively stringent (i.e. high stringent conditions) hybridization conditions (see, e.g., Maniatis et al ., 1982), to DNA sequences presently known to include related gene sequences. Nucleic acid segment embodiments of the invention are defined above.
  • VMP-like gene segment or cDNA To prepare an VMP-like gene segment or cDNA one may follow the teachings disclosed herein and also the teachings of any of patents or scientific documents specifically referenced herein.
  • PCRTM polymerase chain reaction
  • Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCRTM technology of U.S. Patents 4,683,195 and 4,683,202 .
  • VMP genes and DNA segments that are particularly preferred for use in certain aspects of the present methods are those encoding VMP and VMP-related polypeptides.
  • the techniques for cloning DNA molecules i . e ., obtaining a specific coding sequence from a DNA library that is distinct from other portions of DNA, are well known in the art. This can be achieved by, for example, screening an appropriate DNA library which relates to the cloning of a vls gene such as from the variable region of that gene.
  • the screening procedure may be based on the hybridization of oligonucleotide probes, designed from a consideration of portions of the amino acid sequence of known DNA sequences encoding related Borrelia proteins.
  • the operation of such screening protocols is well known to those of skill in the art and are described in detail in the scientific literature, for example, see Sambrook et al ., 1989.
  • the present description in a general and overall sense, also illustrates the isolation and characterization of novel vls gene segments, which encode combinatorial mosaics of expressed and silent regions of the vls gene.
  • the purified nucleic acid segment may consist essentially of the nucleotide sequence of SEQ ID NO:1, their complement or the degenerate variants thereof.
  • nucleic acid segment and DNA segment are used interchangeably and refer to a DNA molecule which has been isolated free of total genomic DNA of a particular species. Therefore, a "purified" DNA or nucleic acid segment as used herein, refers to a DNA segment which contains a VMP coding sequence yet is isolated away from, or purified free from, total genomic DNA, for example, total cDNA or borrelia genomic DNA. Included within the term “DNA segment”, are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like.
  • a DNA segment comprising an isolated or purified vls gene refers to a DNA segment including VMP-related coding sequences isolated substantially away from other naturally occurring genes or protein encoding sequences.
  • the term "gene” is used for simplicity to refer to a functional protein, polypeptide or peptide encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences, cDNA sequences or combinations thereof.
  • isolated substantially away from other coding sequences means that the gene of interest, in this case vls , forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally-occurring coding DNA, such as large chromosomal fragments or other functional genes or cDNA coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man, nor are other portions or contiguous sequences of naturally occurring DNA excluded.
  • the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a VMP-like protein that includes within its amino acid sequence an amino acid sequence in accordance with SEQ ID NO:2.
  • Another preferred embodiment of the present invention is a purified nucleic acid segment that encodes a protein in accordance with SEQ ID NO:2, further defined as a recombinant vector.
  • recombinant vector refers to a vector that has been modified to contain a nucleic acid segment that encodes an VMP protein, or a fragment thereof.
  • the recombinant vector may be further defined as an expression vector comprising a promoter operatively linked to said VMP-encoding nucleic acid segment.
  • a host cell made recombinant with a recombinant vector comprising an vls gene.
  • the recombinant host cell may be a prokaryotic cell.
  • the term "engineered” or "recombinant” cell is intended to refer to a cell into which a recombinant gene, such as a gene encoding VMP, has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced gene. Engineered cells are thus cells having a gene or genes introduced through the hand of man. Recombinantly introduced genes will either be in the form of a copy of a genomic gene or a cDNA gene, or will include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene.
  • the invention concerns isolated DNA segments and recombinant vectors which encode a protein or peptide that includes within its amino acid sequence an amino acid sequence essentially as set forth in SEQ ID NO:2.
  • the DNA segment or vector encodes a full length immunogenic polypeptide, or is intended for use in expressing the immunogenic polypeptide
  • the most preferred sequences are those which are essentially as set forth in SEQ ID NO:2.
  • SEQ ID NO:2 represents the full length protein encoded by the vls gene and that contemplated embodiments include up to the full length sequence and functional variants as well.
  • the invention concerns isolated DNA segments and recombinant vectors that include within their sequence a nucleic acid sequence essentially as set forth in SEQ ID NO:1.
  • the term "essentially as set forth in SEQ ID NO:1," is used in the same sense as described above and means that the nucleic acid sequence substantially corresponds to a portion of SEQ ID NO:1 , and has relatively few codons which are not identical, or functionally equivalent, to the codons of SEQ ID NO:1.
  • the term “functionally equivalent codon” is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, as set forth in Table 4, and also refers to codons that encode biologically equivalent amino acids.
  • amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned.
  • the addition of terminal sequences particularly applies to nucleic acid sequences which may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i . e ., introns, which are known to occur within genes.
  • the present invention also encompasses DNA segments which are complementary, to the sequence set forth in SEQ ID NO:1.
  • Nucleic acid sequences which are "complementary” are those which are capable of base-pairing according to the standard Watson-Crick complementary rules.
  • nucleic acid segments regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. DNA segments with total lengths of about 8000, 7000, 6000, 5000, 4000, 3000, 2000, 1000, 500, 200, 100 and about 50 base pairs in length are also contemplated to be useful.
  • the DNA segments of the present invention encompass biologically functional equivalent VMP-like proteins and peptides. Such sequences may arise as a consequence of codon redundancy and functional equivalency which are known to occur naturally within nucleic acid sequences and the proteins thus encoded.
  • functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man may be introduced through the application of site-directed mutagenesis techniques, e.g. , to introduce improvements to the antigenicity of the VMP-like protein or to test VMP-like mutants in order to examine activity or determine the presence of ViviP-like peptide in various cells and tissues at the molecular level.
  • a preferred embodiment of the present invention is a purified composition comprising a polypeptide having the amino acid sequence in accordance with SEQ ID NO:2.
  • the term "purified” as used herein, is intended to refer to an VMP-related protein composition, wherein the VMP-like protein is purified to any degree relative to its naturally-obtainable state, i . e ., in this case, relative to its purity within a eukaryotic cell extract.
  • VMP-like protein A useful cell for the isolation of VMP-like protein is from borrelia organisms; however, VMP-like protein may also be isolated from various patient specimens, specimens from infected animals, recombinant cells, tissues, isolated subpopulations of tissues, and the like, as will be known to those of skill in the art, in light of the present disclosure.
  • a purified VMP-like protein composition therefore also refers to a polypeptide having the amino acid sequence of SEQ ID NO:2, free from the environment in which it may naturally occur.
  • fusion proteins and peptides e.g. , where the VMP-like protein coding regions are aligned within the same expression unit with other proteins or peptides having desired functions, such as for purification or immunodetection purposes (e . g ., proteins which may be purified by affinity chromatography and enzyme label coding regions, respectively).
  • VMP-like protein a gene that is a convenient means of bacterial expression.
  • VMP-GST glutthione-S-transferase
  • VMP-like proteins may be successfully expressed in eukaryotic expression systems, however, the inventors contemplate that bacterial expression systems may be used for the preparation of VMP for all purposes.
  • the cDNA containing vls gene may be separately expressed in bacterial systems, with the encoded proteins being expressed as fusions with ⁇ -galactosidase, avidin, ubiquitin. Schistosoma japonicum glutathione S-transferase, multiple histidines, epitope-tags and the like. It is believed that bacterial expression will ultimately have advantages over eukaryotic expression in terms of ease of use and quantity of materials obtained thereby.
  • VMP-like proteins transformation of host cells with DNA segments encoding VMP-like proteins will provide a convenient means for obtaining a VMP-like protein. It is also proposed that cDNA, genomic sequences, and combinations thereof, modified by the addition of a eukaryotic or viral promoter, are suitable for eukaryotic expression, as the host cell will, of course, process the genomic transcripts to yield functional mRNA for translation into protein.
  • Another embodiment is a method of preparing a protein composition containing growing recombinant host cell comprising a vector that encodes a protein which includes an amino acid sequence in accordance with SEQ ID NO:2 as defined in the above embodiments, under conditions permitting nucleic acid expression and protein production followed by recovering the protein so produced.
  • the host cell, conditions permitting nucleic acid expression, protein production and iecovery, will be known to those of skill in the art, in light of the present disclosure of the vls gene.
  • a gene or DNA segment encoding an VMP-like polypeptide refers to a DNA segment that contains sequences encoding an VMP-like protein, but is isolated away from, or purified free from, total genomic DNA of the species from which the DNA is obtained.
  • DNA segment includes DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phage, retroviruses, adenoviruses, and the like.
  • gene is used for simplicity to refer to a functional protein or peptide encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences and cDNA sequences. "Isolated substantially away from other coding sequences" means that the gene of interest, in this case, a VMP-like protein encoding gene, forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally-occurring coding DNA, such as large chromosomal fragments or other functional genes or cDNA coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions, such as sequences encoding leader peptides or targeting sequences, later added to the segment by the hand of man.
  • a particular aspect of this invention provides novel ways in which to utilize VMP-encoding DNA segments and recombinant vectors comprising vls DNA segments.
  • VMP-encoding DNA segments and recombinant vectors comprising vls DNA segments.
  • many such vectors are readily available, one particular detailed example of a suitable vector for expression in mammalian cells is that described in U. S. Patent 5,168,050 .
  • a highly purified vector be used, so long as the coding segment employed encodes a VMP-like protein and does not include any coding or regulatory sequences that would have an adverse effect on cells.
  • useful nucleic acid sequences may include additional residues, such as additional non-coding sequences flanking either of the 5' or 3' portions of the coding including, for example, promoter regions, or may include various internal sequences, i . e ., introns, which are known to occur within genes.
  • VMP-encoding gene or DNA molecule After identifying an appropriate VMP-encoding gene or DNA molecule, it may be inserted into any one of the many vectors currently known in the art, so that it will direct the expression and production of the VMP-like protein when incorporated into a host cell.
  • the coding portion of the DNA segment is positioned under the control of a promoter.
  • the promoter may be in the form of the promoter which is naturally associated with a VMP-encoding gene, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon, for example, using recombinant cloning and/or PCRTM technology, in connection with the compositions disclosed herein.
  • a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a vls gene in its natural environment. Such promoters may include those normally associated with other borrelia -inhibitory polypeptide genes, and/or promoters isolated from any other bacterial, viral, eukaryotic, or mammalian cell. Naturally, it will be important to employ a promoter that effectively directs the expression of the DNA segment in the particular cell containing the vector comprising a vls gene or gene segment.
  • promoters to achieve protein expression is generally known to those of skill in the art of molecular biology, for example, see Sambrook et al ., (1989).
  • the promoters employed may be constitutive, or inducible, and can be used under the appropriate conditions to direct high level or regulated expression of the introduced DNA segment.
  • the currently preferred promoters are those such as CMV, RSV LTR, the SV40 promoter alone, and the SV40 promoter in combination with the SV40 enhancer.
  • liposomes are generally known to those of skill in the art (see for example, Couvreur et al ., 1991 which describes the use of liposomes and nanocapsules in the targeted antibiotic therapy of intracellular bacterial infections and diseases). Recently, liposomes were developed with improved serum stability and circulation half-times (Gabizon and Papahadjopoulos, 1988; Allen and Choun, 1987). The following is a brief description of these DNA delivery modes.
  • Nanocapsules can generally entrap compounds in a stable and reproducible way (Henry-Michelland et al ., 1987). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 mm) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention, and such particles may be are easily made, as described (Couvreur et al., 1984; 1988).
  • Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs).
  • MLVs generally have diameters ranging from 25 mm to 4 mm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 ⁇ , containing an aqueous solution in the core.
  • SUVs small unilamellar vesicles
  • Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure.
  • the physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars and drugs.
  • Liposomes interact with cells via four different mechanisms: Endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa , without any association of the liposome contents. It often is difficult to determine which mechanism is operative and more than one may operate at the same time.
  • VMP-like proteins For the expression of VMP-like proteins, once a suitable (full-length if desired) clone or clones have been obtained, whether they be cDNA based or genomic, one may proceed to prepare an expression system for the recombinant preparation of VMP-like proteins.
  • the engineering of DNA segment(s) for expression in a prokaryotic or eukaryotic system may be performed by techniques generally known to those of skill in recombinant expression. It is believed that virtually any expression system may be employed in the expression of VMP-like proteins.
  • VMP-like proteins may be successfully expressed in eukaryotic expression systems, however, it is also envisioned that bacterial expression systems may be preferred for the preparation of VMP-like proteins for all purposes.
  • the cDNA for VMP-like proteins may be separately expressed in bacterial systems, with the encoded proteins being expressed as fusions with b-galactosidase, ubiquitin, Schistosoma japonicum glutathione S-transferase, green fluorescent protein and the like. It is believed that bacterial expression will ultimately have advantages over eukaryotic expression in terms of ease of use and quantity of materials obtained thereby.
  • VMP-like proteins e.g ., baculovirus-based, glutamine synthase-based or dihydrofolate reductase-based systems could be employed.
  • plasmid vectors incorporating an origin of replication and an efficient eukaryotic promoter as exemplified by the eukaryotic vectors of the pCMV series, such as pCMV5, will be of most use.
  • an appropriate polyadenylation site e.g., 5'-AATAAA-3'
  • the poly A addition site is placed about 30 to 2000 nucleotides "downstream" of the termination site of the protein at a position prior to transcription termination.
  • Translational enhancers may also be incorporated as part of the vector DNA.
  • the DNA constructs of the present invention should also preferable contain one or more 5' non-translated leader sequences which may serve to enhance expression of the gene products from the resulting mRNA transcripts.
  • Such sequences may be derived from the promoter selected to express the gene or can be specifically modified to increase translation of the RNA.
  • Such regions may also be obtained from viral RNAs, from suitable eukaryotic genes, or from a synthetic gene sequence (Griffths, et al ., 1993).
  • enhancer sequences may be desirable to increase or alter the translational efficiency of the resultant mRNA.
  • the present invention is not limited to constructs where the enhancer is derived from the native 5'-nontranslated promoter sequence, but may also include non-translated leader sequences derived from other non-related promoters such as other enhancer transcriptional activators or genes.
  • VMPs in accordance herewith.
  • Examples include cell lines typically employed for eukaryotic expression such as 239, AtT-20, HepG2, VERO, HeLa, CHO, WI 38, BHK, COS-7, RIN and MDCK cell lines.
  • VMP-like protein may be "overexpressed", i . e ., expressed in increased levels relative to its natural expression in borrelia cells, or even relative to the expression of other proteins in a recombinant host cell containing VMP-encoding DNA segments.
  • overexpression may be assessed by a variety of methods, including radiolabeling and/or protein purification. However, simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or Western blotting, followed by quantitative analyses, such as densitometric scanning of the resultant gel or blot.
  • a specific increase in the level of the recombinant protein or peptide in comparison to the level in natural VMP-producing animal cells is indicative of overexpression, as is a relative abundance of the specific protein in relation to the other proteins produced by the host cell and, e.g. , visible on a gel.
  • engineered or "recombinant” cell is intended to refer to a cell into which a recombinant gene, such as a gene encoding a VMP peptide has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced gene. Engineered cells are thus cells having a gene or genes introduced through the hand of man. Recombinantly introduced genes will either be in the form of a cDNA gene ( i . e ., they will not contain introns), a copy of a genomic gene, or will include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene.
  • recombinant VMPs may differ from naturally produced VMP in certain ways.
  • the degree of post-translational modifications such as, for example, lipidation, glycosylation and phosphorylation may be different between the recombinant VMP and the VMP polypeptide purified from a natural source, such as Borrelia .
  • the DNA may then be inserted into any one of the many vectors currently known in the art and transferred to a prokaryotic or eukaryotic host cell where it will direct the expression and production of the so-called "recombinant" version of the protein.
  • the recombinant host cell may be selected from a group consisting of S . mutans, E. coli, S. cerevisae. Bacillus sp., Lactococci sp ., Enterococci sp ., or Salmonella sp. In certain preferred embodiments, the recombinant host cell will have a rec A phenotype.
  • the level of expression of a particular recombinant gene can be chosen by evaluating different clones derived from each transfection study; once that line is chosen, the constitutive promoter ensures that the desired level of expression is permanently maintained. It may also be possible to use promoters that are subject to regulation, such as those regulated by the presence of lactose analog or by the expression of bacteriophage T7 DNA polymerase.
  • Recombinant versions of a protein or polypeptide are deemed as part of the present invention.
  • the techniques are based on cloning of a DNA molecule encoding the polypeptide from a DNA library, that is, on obtaining a specific DNA molecule distinct from other DNAs.
  • One may, for example, clone a cDNA molecule, or clone genomic DNA. Techniques such as these would also be appropriate for the production of the VMP-like polypeptides in accordance with the present invention.
  • An aspect of the present invention is the enhanced production of VMP-like proteins by recombinant methodologies in a bacterial host, employing DNA constructs to transform Gram-positive or Gram-negative bacterial cells.
  • Escherichia coli expression systems is well known to those of skill in the art, as is the use of other bacterial species such as Bacillus subtilis or Streptococcus sanguis .
  • FIG. 1 Further aspects of the invention include high expression vectors incorporating DNA encoding novel vls , combinatorial segments and its variants. It is contemplated that vectors providing enhanced expression of VMP in other systems such as S . mutans will also be obtainable. Where it is desirable, modifications of the physical properties of VMP may be sought to increase its solubility or expression in liquid culture.
  • the vls locus may be placed under control of a high expression promoter or the components of the expression system altered to enhance expression.
  • the DNA encoding the VMP-like proteins of the present invention allows for the large scale production and isolation of VMP-like polypeptides. This can be accomplished by directing the expression of the VMP-like polypeptide by cloning the DNA encoding the VMP-like polypeptide into a suitable expression vector. Such an expression vector may then be transformed into a host cell that is able to produce the VMP-like proteins. The VMP-like protein may then be purified, e . g ., by means provided for in this disclosure and utilized in a biologically active form. Non-biologically active recombinant VMP-like proteins may also have utility, e . g ., as an immunogen to prepare anti-VM antibodies.
  • Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized DNA genome, ease of manipulation, high titer, wide target-cell range, and high infectivity.
  • the roughly 36 kB viral genome is bounded by 100-200 base pair (bp) inverted terminal repeats (ITR), in which are contained cis -acting elements necessary for viral DNA replication and packaging.
  • ITR inverted terminal repeats
  • the early (E) and late (L) regions of the genome that contain different transcription units are divided by the onset of viral DNA replication.
  • the E1 region encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes.
  • the expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression, and host cell shut off (Renan, 1990).
  • the products of the late genes (L1, L2, L3, L4 and L5), including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP).
  • MLP located at 16.8 map units
  • TL tripartite leader
  • adenovirus In order for adenovirus to be optimized for gene therapy, it is necessary to maximize the carrying capacity so that large segments of DNA can be included. It also is very desirable to reduce the toxicity and immunologic reaction associated with certain adenoviral products.
  • ITR inverted terminal repeats
  • the packaging signal for viral encapsidation is localized between 194-385 bp (0.5-1.1 map units) at the left end of the viral genome (Hearing et al ., 1987).
  • This signal mimics the protein recognition site in bacteriophage ⁇ DNA where a specific sequence close to the left end, but outside the cohesive end sequence, mediates the binding to proteins that are required for insertion of the DNA into the head structure.
  • E1 substitution vectors of Ad have demonstrated that a 450 bp (0-1.25 map units) fragment at the left end of the viral genome could direct packaging in 293 cells (Levrero et al ., 1991).
  • adenoviral genome can be incorporated into the genome of mammalian cells and the genes encoded thereby expressed. These cell lines are capable of supporting the replication of an adenoviral vector that is deficient in the adenoviral function encoded by the cell line. There also have been reports of complementation of replication deficient adenoviral vectors by "helping" vectors, e.g. , wild-type virus or conditionally defective mutants.
  • VMP-like related proteins and functional variants are also considered part of the invention.
  • truncated and mutated versions of VMP-like protein SEQ ID NO:2
  • any functional version of SEQ ID NO:2, such as truncated species or homologs as defined in the above embodiments, and mutated versions of VMP-like protein are considered as part of the invention.
  • Mutagenized recombinant VMPs may have increased potency and prolonged in vivo half-life, thereby offering more effective long-term treatments. Novel VMPs thus may be obtained by modifications to the vls gene, (such as by site-specific mutagenesis).
  • compositions prepared in accordance with the present invention find use in preventing or ameliorating conditions associated with Borrelia infections, particularly Lyme disease. Such methods generally involve administering a pharmaceutical composition comprising an effective amount of a VMP-like antigen, such as SEQ ID NO:2 or various epitopes thereof.
  • a VMP-like antigen such as SEQ ID NO:2 or various epitopes thereof.
  • Other exemplary compositions may include an effective amount of either a VMP-like variant or a VMP-like encoding nucleic acid composition.
  • Such compositions may also be used to generate an immune response in an animal in such cases where it may be desirable to block the effect of a naturally produced VMP-like protein.
  • nucleic acids which encode a VMP-like protein.
  • the nucleic acid delivery methods may thus entail the administration of one, two, three, or more, homologous VMP-encoding genes.
  • the maximum number of genes that may be applied is limited only by practical considerations, such as the effort involved in simultaneously preparing a large number of gene constructs or even the possibility of eliciting an adverse cytotoxic effect.
  • genes may be two or more distinct genes; or it may be such that a vls gene is combined with another gene and/or another protein, cofactor or other biomolecule; a cytokine gene may even be combined with a gene encoding a cell surface receptor capable of interacting with the polypeptide product of the first gene.
  • genes may be combined on a single genetic construct under control of one or more promoters, or they may be prepared as separate constructs of the same or different types.
  • genes and genetic constructs may be employed.
  • Certain gene combinations may be designed to, or their use may otherwise result in, achieving synergistic effects in affording protection against Borrelia and/or stimulation of an immune response. Any and all such combinations are intended to fall within the scope of the present invention. Indeed, many synergistic effects have been described in the scientific literature, so that one of ordinary skill in the art would readily be able to identify likely synergistic gene combinations, or even gene-protein combinations.
  • nucleic acid segment or gene encoding a VMP-like protein could be administered in combination with further agents, such as, e . g ., proteins or polypeptides or various pharmaceutically active agents. So long as the composition comprises a vls gene, there is virtually no limit to other components which may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues.
  • the nucleic acids may thus be delivered along with various other agents as required in the particular instance.
  • kits comprising VMP-like peptides or VMP-encoding nucleic acid segments comprise another aspect of the present invention.
  • Such kits will generally contain, in suitable container means, a pharmaceutically acceptable formulation of a VMP-like peptide or a VMP-encoding nucleic acid composition.
  • the kit may have a single container means that contains the VMP composition or it may have distinct container means for the VMP composition and other reagents which may be included within such kits.
  • the components of the kit may be provided as liquid solution(s), or as dried powder(s).
  • the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred.
  • the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.
  • Kits may also comprise reagents for detecting VMP-like polypeptides, such as required for immunoassay.
  • the immunodetection reagent will typically comprise a label associated with the antibody or antigen, or associated with a secondary binding ligand.
  • Exemplary ligands might include a secondary antibody directed against the first antibody or antigen or a biotin or avidin (or streptavidin) ligand having an associated label.
  • a number of exemplary labels are known in the art and all such labels may be employed in connection with the present invention.
  • the kits may contain antibody-label conjugates either in fully conjugated form, in the form of intermediates, or as separate moieties to be conjugated by the user of the kit.
  • the container means will generally include at least one via I, test tube, flask, bottle, syringe or other container means, into which the antigen or antibody may be placed, and preferably suitably aliquoted. Where a second binding ligand is provided, the kit will also generally contain a second via I or other container into which this ligand or antibody may be placed.
  • the kits of the present invention will also typically include a means for containing the antibody, antigen, and reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.
  • the present invention contemplates an antibody that is immunoreactive with a polypeptide of the invention.
  • An antibody can be a polyclonal or a monoclonal antibody.
  • an antibody is a monoclonal antibody.
  • Means for preparing and characterizing antibodies are well known in the art (See, e . g ., Howell and Lane, 1988).
  • a polyclonal antibody is prepared by immunizing an animal with an immunogen comprising a polypeptide of the present invention and collecting antisera from that immunized animal.
  • an immunogen comprising a polypeptide of the present invention
  • a wide range of animal species can be used for the production of antisera.
  • an animal used for production of anti-antisera is a rabbit, a mouse, a rat, a hamster or a guinea pig. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.
  • antibodies both polyclonal and monoclonal, specific for VMP-like polypeptides are part of the invention and may be prepared using conventional immunization techniques, as will be generally known to those of skill in the art.
  • a composition containing antigenic epitopes of VMP can be used to immunize one or more experimental animals, such as a rabbit or mouse, which will then proceed to produce specific antibodies against vls expression.
  • Polyclonal antisera may be obtained, after allowing time for antibody generation, simply by bleeding the animal and preparing serum samples from the whole blood.
  • Hybridomas which produce monoclonal antibodies to the selected antigens are identified using standard techniques, such as ELISA and Western blot methods. Hybridoma clones can then be cultured in liquid media and the culture supernatants purified to provide the VMP-specific monoclonal antibodies.
  • the monoclonal antibodies of the present invention will find useful application in standard immunochemical procedures, such as ELISA and Western blot methods, as well as other procedures which may utilize antibody specific to VMP epitopes.
  • monoclonal antibodies specific to the particular polypeptide may be utilized in other useful applications.
  • their use in immunoabsorbent protocols may be useful in purifying native or recombinant VMP species or variants thereof.
  • both poly- and monoclonal antibodies against VMP may be used in a variety of embodiments.
  • they may be employed in antibody cloning protocols to obtain cDNAs or genes encoding VMP or related proteins. They may also be used in inhibition studies to analyze the effects of VP in cells or animals.
  • Anti-VMP antibodies will also be useful in immunolocalization studies to analyze the distribution of VMP peptides during various cellular events, for example, to determine the cellular or tissue-specific distribution of the VP peptide under different physiological conditions.
  • a particularly useful application of such antibodies is in purifying native or recombinant VMP, for example, using an antibody affinity column. The operation of all such immunological techniques will be known to those of skill in the art in light of the present disclosure.
  • the present work discloses the identification and characterization of an elaborate genetic system in the Lyme disease spirochete Borrelia burgdorferi that promotes extensive antigenic variation of a surface-exposed lipoprotein, VlsE.
  • a 28-kilobase linear plasmid of B. burgdorferi B31 (pBB28La) was found to contain a vmp -like sequence ( vls ) locus that closely resembles the variable major protein ( vmp ) system for antigenic variation of relapsing fever organisms.
  • the vls locus resembles the vmp system of B. hermsii in both sequence and genetic organization. There is some sequence homology between these two systems, particularly between the visE and large vmp genes. This is exemplified by direct sequence comparison between vlsE and vmp17, which have homology throughout their predicted amino acid sequences ( FIG. 3A ). The vlsE and silent vls cassettes also have a closer degree of homology to small vmps and B. burgdorferi ospC genes.
  • both the vls and vmp systems have a single expression site encoding a surface-localized lipoprotein, as well as multiple unexpressed sequences (Plasterk et al ., 1985; Barbour et al ., 1991a). Finally, the expression sites for both systems are located near one of the telomeres of their respective linear plasmids (Kitten and Barbour, 1990; Barbour et al ., 1991b). These observations suggest that the vls locus may provide the Lyme disease Borreliae with the capability of antigenic variation analogous to the vmp system of B. hermsii (Barbour, 1993).
  • B. hermsii possesses at least two vmp -containing linear plasmids (Meier et al ., 1985; Plasterk et al ., 1985), whereas only one vls -containing linear plasmid was detected in Lyme disease Borreliae under hybridization conditions ( FIGs. 1A and1B).
  • the silent vmp genes are separated by intergenic noncoding regions and arranged in either orientation (Barbour et al ., 1991a), but the silent vls cassettes are organized head-to-tail as a single open reading frame throughout almost the entire region ( FIGs. 2A and 2B ).
  • the silent vmp genes lack promoter sequences, but most encode complete or nearly complete open reading frames with their own ribosome-binding sites (Barbour et al ., 1991a).
  • the vls cassettes represent only the central third of the expression site.
  • each phase of B. hermsii infection is caused predominantly by organisms expressing a single vmp allele (Meier et al ., 1985; Plasterk et al ., 1985), whereas a high degree of vlsE allelic variation occurs among organisms isolated even from a small ear biopsy specimen during B. burgdorferi infection ( FIGs. 5A , 5B and 5C ).
  • sequence changes at the vlsE site may result from genetic recombination with sequences from the silent vls cassettes.
  • sequences from the silent vls cassettes Despite considerable sequence variations within the vls region of different vlsE alleles, the sequence examined outside the 17-bp direct repeats remained unchanged ( FIG. 5B and FIG. 5C ). Within the vls region, the changes are not random but are clustered predominantly in six highly variable regions found in 15 silent vls cassettes ( FIG. 3B ). Nearly all of the sequence variations observed in the mouse isolates are identical to portions of the silent vls cassettes, although the combinations of the sequence variations made each of these alleles unique.
  • the inventors have shown that B. burgdorferi undergoes an unusual type of genetic variation ( FIG. 7 ): (i) the vls cassettes contain conserved and variable regions; (ii) the conserved sequences facilitate recombination between the expressed and silent vls sequences, probably by a non-reciprocal gene conversion mechanism; (iii) the conserved 17-bp direct repeat sequences may be involved in alignment of the vls sequences during recombination or in binding of proposed site-specific recombinase(s); (iv) through multiple recombination events, portions of the expression site are replaced by segments from several silent vls cassettes, resulting in a vast array of potential vlsE alleles; and (v) the site-specific mechanism is activated in vivo, resulting in a high rate of recombination.
  • pilS silent copies containing portions of the pilin genes are found over a wide range on the gonococcal chromosome.
  • a single gonococcal clone expressing one pilin stereotype can give rise to a large number of progeny that express antigenically distinctive pilin variants (Meyer et al ., 1982; Hagblom et al ., 1985; Segal et al ., 1986).
  • the recombination between the expression and silent loci occurs predominantly through a non-reciprocal gene conversion mechanism (Haas and Meyer, 1986; Koomey et al ., 1987).
  • the coding sequences of the Neisseria pilin variants are divided into constant, semi-variable, and hypervariable regions (Haas and Meyer, 1986), which are analogous to the conserved and variable regions of the vls cassettes ( FIG. 3B , FIG. 5B and FIG. 5C ).
  • the constant regions and a conserved DNA sequence (Sma/Cla repeat) located at the 3' end of all pilin loci are though to pair the regions involved in recombination events (Wainwright et al ., 1994).
  • the 17-bp direct repeats ( FIG. 2C ) and the conserved regions ( FIG. 3B ) of the vls cassettes may play a similar role in recombination events.
  • the silent loci of gonococcal pilin genes contain different regions of the complete pilin genes (Haas and Meyer, 1986), whereas the silent vls cassettes of B. burgdorferi represent only the central cassette region of the vlsE gene ( FIG. 3B ).
  • Non-reciprocal recombinations also occurs between the expressed and the silent genes encoding variant surface glycoproteins (Vsgs) in African trypanosomes (Donelson, 1995). Based on similarities between the vls locus and the multi-gene families of the other pathogenic microorganisms, it is likely that a unidirectional gene conversion mechanism is also active in the vls locus. However, there is not as yet any data regarding the preservation of the silent vls cassettes, and the exact mechanism of vls recombination remains to be determined.
  • VlsE is a surface-exposed lipoprotein, as indicated by proteinase K digestion ( FIGs. 4A and 4B ) and [ 3 H]-palmitate radiolabeling studies, this proposed antigenic variation may allow Lyme disease Borreliae to survive immune attack targeted against VlsE.
  • VlsE B. burgdorferi surface proteins
  • VmpB exhibited more severe arthritic manifestations
  • VmpA had more severe central nervous system involvement
  • the numbers of Borreliae present in the joints and blood of serotype B-infected mice were much higher than those of mice infected with serotype A, consistent with a relationship between Vmp serotype and disease severity (Pennington et al, 1997).
  • Neisseria pilin Long et al ., 1980; Rudel et al ., 1992; Nassif et al ., 1993; Jonsson et al , 1994
  • Opa proteins Kersch et al , 1993
  • burgdorferi clones with or without plasmid pBB28La showed similar growth rates in culture medium.
  • pBB28La is readily lost during in vitro subcultures as early as passage 5. Therefore, presence of pBB28La appears to have little if any effect on in vitro growth, yet has a profound effect on the ability to infect mammalian host.
  • VIsE (or, potentially, other genes encoded by pBB28La) appears to have another important but undefined function which is unrelated to antigenic variation.
  • SCID severe combined immunodeficiency
  • Bb clones lacking pBB28La appears to occur early in infection (within the first week), before the adaptive immune response would be expected to exert significant selection pressure. Therefore, it is likely that VlsE plays an important role in some aspect of infection (e.g.
  • Vmps variable major proteins
  • vmp 7 and vmp 17 and small vmp genes such as vmp 1 and vmp 3 are approximately 1 kb and 0.6 kb in size, respectively.
  • Each organism contains both small and large vmp genes in a unexpressed (silent) form in the so-called storage plasmids (Plasterk et al ., 1985). Only one vmp gene located near one of the telomeres of a different plasmid (called the expression plasmid) is expressed in each organism (Kitten and Barbour, 1990; Barbour et al ., 1991a).
  • Antigenic variation occurs when the expressed vmp is replaced completely or partially by one of the silent vmp genes at the telomeric expression site through interplasmic recombination (Meier et al ., 1985; Plasterk et al ., 1985; Barbour et al ., 1991b), intraplasmic recombination (Restrepo et al ., 1994), and post-switch rearrangement (Restrepo and Barbour, 1994).
  • the antigenic switch occurs spontaneously at a frequency of 10 -3 to 10 -4 per generation (Stoenner et al ., 1982).
  • vmp -like sequence A genetic locus (called vmp -like sequence or vls ) has been identified and characterized in B. burgdorferi that surprisingly resembles the vmp system of B. hermsii.
  • a vls expression site ( vlsE ) and 15 additional silent vls cassettes were identified on a 28-kb linear plasmid (designated pBB28La).
  • the presence of pBB28La correlates with the high-infectivity phenotype in B. burgdorferi sensu lato strains tested.
  • vlsE located near a telomere of pBB28La, encodes a surface-exposed lipoprotein.
  • the present invention illustrates the rapid occurrence of promiscuous recombination at the vls expression site ( vls E), resulting in a combinatorial form of genetic and antigenic variation at the vls E site.
  • Antigenic variation at the vls site has been detected using an in vivo selection approach.
  • each vlsE cassette is unique. At the nucleotide level each vlsE cassette is comprised of regions identical to several of the silent vls cassettes. This promiscuous recombination of silent vls cassette segments causes a combinatorial diversity at the vlsE expression site, similar to the diversity possible in the immunoglobulin and T cell-receptor variable regions. In contrast, antigenic variation in relapsing fever organisms usually involves replacement of the entire gene at the expression site with one of the 'silent' VMP genes. Moreover, a single VMP serotype is predominant during each relapse.
  • the present invention discloses a repetitive DNA sequence ⁇ 500 bp in length which is present in multiple, nonidentical copies in a 28 kb linear plasmid of infectious Borrelia burgdorferi, the causative agent of Lyme disease.
  • These DNA sequences encode polypeptides which have sequence similarity to the Variable Major Proteins (VMPs) of relapsing fever Borreliae (such as B. hermsii ) .
  • VMPs are highly antigenic surface proteins which the relapsing fever Borreliae are able to change through a genetic recombination mechanism, thereby evading the immune response.
  • Antibodies against a particular VMP are protective, resulting in rapid clearance of bacteria of the corresponding serotype.
  • VMPs Variable Major Proteins
  • VMP-like sequences ( vls ) are present on a 28 kb linear plasmid, and this plasmid appears to encode virulence factor(s) required for infectivity.
  • the sequence of a 16 kb region of this plasmid contains at least 20 copies of the VMP-like sequence.
  • the inventors have identified genes and gene products that appear to be important in the infectivity and pathogenesis of B. burgdorferi.
  • HP B31 high-passage (HP) and low-passage (LP) uncloned populations of B. burgdorferi strain B31 were used as a source of DNA for subtractive hybridization.
  • HP B31 was cultured in vitro for ⁇ 1,000 passages and found to be noninfectious, whereas LP B31 passages in vitro ⁇ 5 times remains infectious in the C3H/HeN mouse model.
  • the plasmid DNA of each strain was purified.
  • the DNA of HP B31 was randomly sheared by ultrasonication, whereas the DNA of LP B31 was digested to completion with the restriction enzyme Sau 3AI.
  • the DNA of the two strains was denatured by heating to 100°C, mixed at a ratio of 50:1 HP DNA to LP DNA, and allowed to hybridize with the sheared HP DNA; as a result, the Sau 3AI restriction sites were not regenerated. Unique segments of the LP DNA tend to hybridize with the complementary LP DNA strand, and the Sau 3AI "sticky ends" are regenerated.
  • a portion of the hybridized mixture was ligated into pBluescript II SK- (Stratagene) that had been treated previously with Bam HI and alkaline phosphatase. The ligated preparation was used to transform E .
  • coli XL-1 Blue cells and transformants were selected by plating the bacteria on Luria broth (LB) agar plates containing ampicillin and isopropyl thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-D-galactoside (X-gal). Any resulting white colonies ( E. coli containing a plasmid with a DNA insert) were selected for further study and sequence analysis.
  • LB Luria broth
  • IPTG ampicillin and isopropyl thiogalactopyranoside
  • X-gal 5-bromo-4-chloro-3-indolyl-D-galactoside
  • pJRZ53 contained DNA encoding a single, contiguous open reading frame (ORF) 562 bp in length.
  • ORF open reading frame
  • the deduced amino acid sequence of this ORF had significant homology with Vmp proteins of B. hermsii , most notably Vmp17, Vmp21, Vmp7, and Vmp25 (27.2 to 20.3% identity, 50.0 to 56.8% similarity).
  • Hybridization of pJRZ53 with Southern blots of B. burgdorferi plasmids showed that this VMP-like DNA sequence was localized on a 28 kb linear plasmid.
  • Additional DNA recombinants containing sequences hybridizing with pJRZ53 were derived from a Pst I library of B. burgdorferi B31 plasmid DNA.
  • B. burgdorferi B31 plasmid DNA was treated with several restriction enzymes to determine the best combination for cloning a larger fragment containing the pJYZ53 sequence.
  • numerous bands hybridizing with the pJRZ53 probe were present in DNA digested with Pst I, Rsa I, Sau 3AI and other enzymes. This result demonstrated that multiple sequences resembling the pJRZ53 insert were present in the 28 kb plasmid.
  • Alignment of the 5' and 3' regions of pJRZ33-31 shows highly homologous repeats in the DNA sequence of recombinant clone pJRZ53-31.
  • the DNA sequence from the 5' (nt 1-578) and 3' (nt 579-1143) regions were aligned using the GCG program GAP. There is 93% identity between the 5' and 3' regions.
  • the deduced amino acid sequences of the DNA regions were aligned using the GCG program GAP. The overall sequence similarity and identity are 92% and 85%, respectively.
  • Plasmid profiles in the same gels used for Southern blot hybridization did not reveal any difference in ethidium bromide staining in the region of the 28 kb plasmid, due to the presence of several other comigrating plasmids.
  • the one low infectivity clone that contained the plasmid may lack a functional gene or genes encoding other virulence factors.
  • a map of the 28 kb linear plasmid (designated pBb28L) showed a 16 kb fragment of pBb28L of the bacterial clone B31-5A3 had been cloned into the vector lambda Dash II (Stratagene, LaJolla, CA). Briefly, a preparation of plasmid DNA was treated with S1 nuclease to disrupt the covalently closed ends (telomeres) of the linear plasmids. After treatment with Klenow fragment of DNA polymerase, an oligonucleotide linker containing an Eco RI site was ligated onto the ends.
  • the preparation was then treated with Eco RI (to cleave the DNA both at the linker and at a previously mapped internal Eco RI site) and ligated into the Eco RI site of lambda Dash Il.
  • Clones containing the pJRZ53 sequence were identified by hybridization, and included two overlapping clones 12 kb and 16 kb in length. Partial sequence analysis of the sequence of the 16 kb fragment revealed the presence of at least 17 VMP-like sequences within this region.
  • the sequences obtained indicate the presence of at least one open reading frame representing an expression site ( vlsE1 ) and at least 16 additional nonidentical, apparently 'silent' (nonexpressed) vls cassettes.
  • a consensus ribosome binding site (RBS, underlined) is located 8 nucleotides (nt) upstream of the predicted translational start site at nt 75-77.
  • the predicted product, VlsE1 has a molecular weight of 35,881 kDa.
  • the first 19 amino acids of the predicted N-terminus contain a possible signal peptide sequence, with a motif of a charged N-terminus, a hydrophobic region, and a potential signal peptidase II cleavage site (FINC, double-underlined) resembling those found in other Borrelial lipoproteins.
  • the predicted polypeptide size after cleavage at this site is 33,957 kDa, and the predicted isoelectric point is 7.3. Except for the signal peptide, the predicted protein is largely hydrophilic.
  • the putative stop codon is located at nt 1143-1145, only 82 nt from the telomeric end of pBb28L.
  • vlsE1 in the high infectivity B. burgdorferi B31 Clone 3 was verified by Northern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCRTM). Hybridization of radiolabelled pJRZ53 insert to blots of RNA separated by agarose electrophoresis indicated the presence of a transcript containing a homologous sequence.
  • RT-PCRTM primers corresponding to nt 835-857 (plus strand) and nt 1010-1032 (minus strand) of the sequence in FIG. 2C were constructed. The minus strand primer was used in combination with AMV reverse transcriptase and RNA isolated from B31 clone 3 to produce a cDNA product.
  • the cDNA was then amplified by standard PCRTM using the plus and minus primers, resulting in a 198 bp product detectable by ethidium bromide staining of agarose gels.
  • the PCRTM product was ligated into the pCRII vector (Invitrogen), and three independently-derived clones yielded sequences identical to that shown in SEQ ID NO:1 and SEQ ID NO:3.
  • Control preparations consisted of reactions identical except for the omission of reverse transcriptase; no product was detected. This result demonstrated that vlsE1 is transcribed in B. burgdorferi B31 Clone 3 organisms.
  • the DNA sequence of a proposed 'storage site' contains at least 15 contiguous copies of the vls sequence of SEQ ID NO:1 and SEQ ID NO:3.
  • the beginning and end of each vls 'cassette' was selected to match the repetitive sequence ( vls1 ) in vlsE1 .
  • the vls cassettes identified thus far range from 474 to 582 nt in length; length variation is primarily due to short insertions or deletions in multiples of three nucleotides, indicating selective preservation of the open reading frames. Longer deletions are seen in vls7, vls8, and vls10. vls14 and vls16 each contain one frameshift, and vls11 contains one stop codon. Otherwise, the 7766 bp sequence of SEQ ID NO:1 and SEQ ID NO:3 represents one contiguous open reading frame.
  • vls cassettes exhibit a remarkable degree of sequence conservation at both the DNA and encoded amino acid levels, see FIGs .
  • Nucleotide sequences of B. burgdorferi B31 vls were aligned using the GCG program PILEUP.
  • vls1 corresponds to nt 420-1003 in the sequence of FIG. 4 and FIG. 5 .
  • the vls sequences have 90.0% to 96.1% nucleotide sequence identity ( FIG. 6 ), and 76.9% to 91.4% predicted amino acid sequence identity ( FIG. 7 ). None of the vls copies identified thus far have complete sequence identity, but all are closely related.
  • Table 3 shows the vls segments identified and indicates the positions at which the segments may be found as part of SEQ ID NO:1 and SEQ ID NO:3. Repeat recombinant segments are identified as "repeats".
  • TABLE 3 CASSETTE (vis) POSITION IN SEQ ID NO:3 REPEAT position in SEQ ID NO:3 vis 2 ⁇ 205>-711 (truncated at 5' end) 711-727 vis 3 712-1293 1293-1309 vis 4 1294-1869 1869-1885 vis 5 1870-2439 2439-2456 vis 6 2440-3009 3009-3025 vis 7 3010-3483 3483-3499 vis 8 3484-3990 3990-4006 vis 9 3991-4548 4548-4557 vis 10 4549-5058 5058-5074 vis 11 5059-5652 5652-5668 vis 12 4653-6219 6219-6253 vis 13 6220-6789 6789-6805 vis 14 6846-7373 7373-7389 vis 15 7274-7946
  • the degree of sequence similarity between the VMP-like sequences and B. hermsii VMP proteins were exemplified by an alignment of the predicted translation product of vlsE1 with some of the most similar VMP sequences ( vmp 17, vmp 21, vmp7 ). Regions of similarity are interspersed among areas of low sequence identity.
  • the G+C contents of the B. burgdorferi VMP-like sequences are quite high ( e . g ., 49.9% for pJRZ53-31) as compared to the genomic B. burgdorferi G+C content (27 to 30%) or that of B. hermsii VMP genes ( e.g., 37% for vmp17 ).
  • the sequence similarity at the protein level may be due to divergent or convergent evolution. It is also possible that the VMP-like sequences were acquired from another organism, given the different G+C content.
  • vlsE1 The expressed copy of vls (vlsE1) has been identified and sequenced. A segment of the vlsE gene corresponding to the cassette region has been subcloned into the pGEX-2T expression vector, and the resulting GST-vls1 fusion protein product produced and purified. Antibodies against the recombinant protein have been used for identification of the native protein in SDS-PAGE and two dimensional gel electrophoresis patterns of B. burgdorferi proteins by immunoblotting. Infected patients and animals produced antibodies against the protein which were detected by immunoblot analysis using the recombinant protein as antigen ( FIGs. 6C, 6D and 6E ).
  • the purified recombinant protein may be used for immunization of mice and other animals to determine whether antibodies or cellular responses against the protein are protective against infection with B. burgdorferi and other Lyme disease Borreliae. Such animal studies would determine the feasibility of vaccination of humans and animals with Vls protein sequences or DNA sequences for immunoprophylaxis.
  • ELISAs may be used in conjunction with the invention.
  • proteins or peptides incorporating Borrelia VMP-like antigenic sequences are immobilized onto a selected surface, preferably a surface exhibiting a protein affinity such as the wells of a polystyrene microtiter plate.
  • a nonspecific protein that is known to be antigenically neutral with regard to the test antisera such as bovine serum albumin (BSA), casein or solutions of powdered milk.
  • BSA bovine serum albumin
  • casein casein
  • the immobilizing surface is contacted with the antisera or clinical or biological extract to be tested in a manner conducive to immune complex (antigen/antibody) formation.
  • Such conditions preferably include diluting the antisera with diluents such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween®. These added agents also tend to assist in the reduction of nonspecific background.
  • the layered antisera is then allowed to incubate for from about 2 to about 4 hr, at temperatures preferably on the order of about 25° to about 27°C. Following incubation, the antisera-contacted surface is washed so as to remove non-immunocomplexed material.
  • a preferred washing procedure includes washing with a solution such as PBS/Tween®, or borate buffer.
  • the occurrence and even amount of immunocomplex formation may be determined by subjecting same to a second antibody having specificity for the first.
  • the second antibody will preferably have an associated enzyme that will generate a color development upon incubating with an appropriate chromogenic substrate.
  • a urease, alkaline phosphatase or peroxidase-conjugated anti-human IgG for a period of time and under conditions which favor the development of immunocomplex formation (e . g ., incubation for 2 hr at room temperature in a PBS-containing solution such as PBS/Tween®).
  • the amount of label is quantified by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline)-6-sulfonic acid (ABTS) and H 2 O 2 , in the case of peroxidase as the enzyme label. Quantitation is then achieved by measuring the degree of color generation, e . g ., using a visible spectrum spectrophotometer.
  • a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline)-6-sulfonic acid (ABTS) and H 2 O 2 , in the case of peroxidase as the enzyme label.
  • Quantitation is then achieved by measuring the degree of color generation, e . g ., using a visible spectrum spectrophotometer.
  • the present invention is also directed to protein or peptide compositions, free from total cells and other peptides, which comprise a purified protein or peptide which incorporates an epitope that is immunologically cross-reactive with one or more anti- Borrelia VMP-like antibodies.
  • the term "incorporating an epitope(s) that is immunologically cross-reactive with one or more anti-VMP-like antibodies” is intended to refer to a peptide or protein antigen which includes a primary, secondary or tertiary structure similar to an epitope located within a Borrelia VMP-like polypeptide.
  • the level of similarity will generally be to such a degree that monoclonal or polyclonal antibodies directed against the Borrelia VMP-like polypeptide will also bind to, react with, or otherwise recognize, the cross-reactive peptide or protein antigen.
  • Various immunoassay methods may be employed in conjunction with such antibodies, such as, for example, Western blotting, ELISA, RIA, and the like, all of which are known to those of skill in the art.
  • Preferred peptides for use in accordance with the present invention will generally be on the order of about 8 to about 20 amino acids in length. It is proposed that shorter antigenic Borrelia VMP-like-derived peptide sequences will provide advantages in certain circumstances, for example, in the preparation of vaccines or in immunologic detection assays. Exemplary advantages include the ease of preparation and purification, the relatively low cost and improved reproducibility of production, and advantageous biodistribution.
  • an epitopic core sequence is a relatively short stretch of amino acids that is "complementary" to, and therefore will bind, antigen binding sites on transferring-binding protein antibodies. Additionally or alternatively, an epitopic core sequence is one that will elicit antibodies that are cross-reactive with antibodies directed against the peptide compositions of the present invention. It will be understood that in the context of the present disclosure, the term “complementary” refers to amino acids or peptides that exhibit an attractive force towards each other. Thus, certain epitope core sequences of the present invention may be operationally defined in terms of their ability to compete with or perhaps displace the binding of the desired protein antigen with the corresponding protein-directed antisera
  • the size of the polypeptide antigen is not believed to be particularly crucial, so long as it is at least large enough to carry the identified core sequence or sequences.
  • the smallest useful core sequence expected by the present disclosure would generally be on the order of 8 or 25.
  • this size will generally correspond to the smallest peptide antigens prepared in accordance with the invention.
  • the size of the antigen may be larger where desired, so long as it contains a basic epitopic core sequence.
  • Syntheses of epitopic sequences, or peptides which include an antigenic epitope within their sequence are readily achieved using conventional synthetic techniques such as the solid phase method ( e . g ., through the use of commercially available peptide synthesizer such as an Applied Biosystems Model 430A Peptide Synthesizer). Peptide antigens synthesized in this manner may then be aliquoted in predetermined amounts and stored in conventional manners, such as in aqueous solutions or, even more preferably, in a powder or lyophilized state pending use.
  • peptides may be readily stored in aqueous solutions for fairly long periods of time if desired, e.g ., up to six months or more, in virtually any aqueous solution without appreciable degradation or loss of antigenic activity.
  • agents including buffers such as Tris or phosphate buffers to maintain a pH of about 7.0 to about 7.5.
  • agents which will inhibit microbial growth such as sodium azide or Merthiolate.
  • the peptides are stored in a lyophilized or powdered state, they may be stored virtually indefinitely, e . g ., in metered aliquots that may be rehydrated with a predetermined amount of water (preferably distilled) or buffer prior to use.
  • the antibodies of the present invention are particularly useful for the isolation of antigens by immunoprecipitation.
  • Immunoprecipitation involves the separation of the target antigen component from a complex mixture, and is used to discriminate or isolate minute amounts of protein.
  • For the isolation of membrane proteins cells must be solubilized into detergent micelles.
  • Nonionic salts are preferred, since other agents such as bile salts, precipitate at acid pH or in the presence of bivalent cations.
  • the antibodies of the present invention are useful for the close juxtaposition of two antigens. This is particularly useful for increasing the localized concentration of antigens, e.g ., enzyme-substrate pairs.
  • compositions of the present invention will find great use in immunoblot or western blot analysis.
  • the anti -Borrelia VMP-like antibodies may be used as high-affinity primary reagents for the identification of proteins immobilized onto a solid support matrix, such as nitrocellulose, nylon or combinations thereof.
  • a solid support matrix such as nitrocellulose, nylon or combinations thereof.
  • immunoprecipitation followed by gel electrophoresis, these may be used as a single step reagent for use in detecting antigens against which secondary reagents used in the detection of the antigen cause an adverse background.
  • the antigens studied are immunoglobulins (precluding the use of immunoglobulins binding bacterial cell wall components), the antigens studied cross-react with the detecting agent, or they migrate at the same relative molecular weight as a cross-reacting signal.
  • Immunologically-based detection methods for use in conjunction with Western blotting include enzymatically-, radiolabel-, or fluorescently-tagged secondary antibodies against the toxin moiety are considered to be of particular use in this regard.
  • vaccines which contain Borrelia VMP-like immunogenic peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251 ; 4,601,903 ; 4,599,231 ; 4,599,230 ; 4,596,792 ; and 4,578,770 .
  • Such vaccines are prepared as injectables. Either as liquid solutions or suspensions: solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified.
  • the active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof
  • the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines.
  • Vaccines are for conventional administration parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations.
  • traditional binders and carriers may include, for example, polyalkalene glycols or triglycerides: such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10%, preferably about 1 to about 2%.
  • Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain about 10 to about 95% of active ingredient, preferably about 25 to about 70%.
  • the Borrelia VMP-like-derived immunogenic peptides of the present invention may be formulated into the vaccine as neutral or salt forms.
  • Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the peptide) and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like, Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • the quantity to be administered depends on the subject to be treated, including, e . g ., the capacity of the individual's immune system to synthesize antibodies, and the degree of protection desired.
  • Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by subsequent inoculations or other administrations.
  • Any of the conventional methods for administration of a vaccine are applicable. These are believed to include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection or the like.
  • the dosage of the vaccine will depend on the route of administration and will vary according to the size of the host.
  • Various methods of achieving adjuvant effect for the vaccine includes use of agents such as aluminum hydroxide or phosphate (alum), commonly used as about 0.05 to about 0.1% solution in phosphate buffered saline, admixture with synthetic polymers of sugars (Carbopol®) used as an about 0.25% solution, aggregation of the protein in the vaccine by heat treatment with temperatures ranging between about 70° to about 101°C for a 30-second to 2-minute period, respectively. Aggregation by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as C.
  • Fab pepsin treated
  • parvum or endotoxins or lipopolysaccharide components of Gram-negative bacteria emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with a 20% solution of a perfluorocarbon (Fluosol-DA®) used as a block substitute may also be employed.
  • physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with a 20% solution of a perfluorocarbon (Fluosol-DA®) used as a block substitute may also be employed.
  • the vaccine will be desirable to have multiple administrations of the vaccine, usually not exceeding six vaccinations, more usually not exceeding four vaccinations and preferably one or more, usually at least about three vaccinations.
  • the vaccinations will normally be at from two to twelve week intervals, more usually from three to five week intervals. Periodic boosters at intervals of 1-5 years, usually three years, will be desirable to maintain protective levels of the antibodies.
  • the course of the immunization may be followed by assays for antibodies for the supernatant antigens.
  • the assays may be performed by labeling with conventional labels, such as radionuclides, enzymes, fluorescents, and the like. These techniques are well known and may be found in a wide variety of patents, such as U.S. Patent Nos. 3,791,932 ; 4,174,384 and 3,949,064 , as illustrative of these types of assays.
  • a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a DNA segment encoding a Borrelia VMP-like peptide in its natural environment.
  • promoters may include promoters normally associated with other genes, and/or promoters isolated from any viral, prokaryotic (e . g ., bacterial), eukaryotic ( e . g ., fungal, yeast, plant, or animal) cell, and particularly those of mammalian cells.
  • promoter that effectively directs the expression of the DNA segment in the cell type, organism, or even animal, chosen for expression.
  • the use of promoter and cell type combinations for protein expression is generally known to those of skill in the art of molecular biology, for example, see Sambrook et al ., 1989.
  • the promoters employed may be constitutive, or inducible, and can be used under the appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins or peptides.
  • promoter/expression systems contemplated for use in high-level expression include, but are not limited to, the Pichia expression vector system (Pharmacia LKB Biotechnology), a baculovirus system for expression in insect cells, or any suitable yeast or bacterial expression system.
  • DNA segments encoding the entire peptide sequence being most preferred.
  • DNA segments that encode Borrelia VMP-like peptide antigens from about 10 to about 100 amino acids in length, or more preferably, from about 20 to about 80 amino acids in length, or even more preferably, from about 30 to about 70 amino acids in length are illustrated to be particularly useful.
  • nucleic acid sequences illustrated herein also have a variety of other uses. For example, they also have utility as probes or primers in nucleic acid hybridization embodiments. As such, it is contemplated that nucleic acid segments that comprise a sequence region that consists of at least an about 20-nucleotide long contiguous sequence that has the same sequence as, or is complementary to, an about 20-nucleotide long contiguous DNA segment of SEQ ID NO:1 will find particular utility. Longer contiguous identical or complementary sequences, e.g. , those of about 20, 30, 40, 50, 100, 200, (including all intermediate lengths) and even those up to and including about 1227-bp (full-length) sequences will also be of use.
  • hybridization probe of about 20 nucleotides in length allows the formation of a duplex molecule that is both stable and selective.
  • Molecules having contiguous complementary sequences over stretches greater than 20 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained.
  • fragments may also be obtained by other techniques such as, e . g ., by mechanical shearing or by restriction enzyme digestion.
  • Small nucleic acid segments or fragments may be readily prepared by, for example directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer.
  • fragments may be obtained by application of nucleic acid reproduction technology, such as PCRTM, by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology.
  • the nucleotide sequences may be used for their ability to selectively form duplex molecules with complementary stretches of DNA fragments.
  • one will desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence.
  • relatively stringent conditions i.e., conditions of high stringency where one will select relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.15 M NaCl at temperatures of about 50°C to about 70°C.
  • Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating Borrelia VMP-like-encoding DNA segments.
  • nucleic acid sequences of the present invention in combination with an appropriate means, such as a label, for determining hybridization.
  • appropriate indicator means include fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detectable signal.
  • fluorescent label or an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmental undesirable reagents.
  • enzyme tags colorimetric indicator substrates are known that can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.
  • the hybridization probes described herein will be useful both as reagents in solution hybridization as well as in embodiments employing a solid phase.
  • the test DNA or RNA
  • the test DNA is adsorbed or otherwise affixed to a selected matrix or surface.
  • This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired conditions.
  • the selected conditions will depend on the particular circumstances based on the particular criteria required (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.).
  • specific hybridization is detected, or even quantitated, by means of the label.
  • Modification and changes may be made in the structure of the peptides of the present invention and DNA segments which encode them and still obtain a functional molecule that encodes a protein or peptide with desirable characteristics.
  • the following is a discussion based upon changing the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule.
  • the amino acid changes may be achieved by changing the codons of the DNA sequence, according to the following codon table: TABLE 4 Amino Acids Codons Alanine Ala A GCA GCC GCG GCU Cysteine Cys C UGC UGU Aspartic acid Asp D GAC GAU Glutamic acid Glu E GAA GAG Phenylalanine Phe F UUC UUU Glycine Gly G GGA GGC GGG GGU Histidine His H CAC CAU Isoleucine Ile I AUA AUC AUU Lysine Lys K AAA AAG Leucine Leu L UUA UUG CUA CUC CUG CUU Methionine Met M AUG Asparagine Asn N AAC AAU Proline Pro P CCA CCC CCG CCU Glutamine Gln Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG CGU Serine Ser S AGC AGU UCA UCC UCG UCU Threonine Thr T ACA ACC ACG ACU
  • amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.
  • the hydropathic index of amino acids may be considered.
  • the importance of the hydropathic amino acid index in confeming interactive biologic fimction on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporate herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.
  • Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics (Kyte and Dooliule, 1982), these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-45).
  • amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i . e ., still obtain a biological functionally equivalent protein.
  • substitution of amino acids whose hydropathic indices are within ⁇ 2 is preferred, those which are within ⁇ 1 are particularly preferred, and those within ⁇ 0.5 are even more particularly prefencd.
  • hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ⁇ 1); glutamate (+3.0 ⁇ 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ⁇ 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).
  • an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein.
  • substitution of amino acids whose hydrophilicity values are within ⁇ 2 is preferred, those which are within ⁇ 1 are particularly preferred, and those within ⁇ 0.5 are even more particularly preferred.
  • amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.
  • Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.
  • Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA.
  • the technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA.
  • Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed.
  • a primer of about 17 to 25 nucleotides in length is preferred, with about 1 to 10 residues on both sides of the junction of the sequence being altered.
  • the technique of site-specific mutagenesis is well known in the art, as exemplified by various publications.
  • the technique typically employs a phage vector which exists in both a single stranded and double stranded form.
  • Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially available and their use is generally well known to those skilled in the art.
  • Double stranded plasmids are also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage.
  • site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double stranded vector which includes within its sequence a DNA sequence which encodes the desired peptide.
  • An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as E. coli polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand.
  • DNA polymerizing enzymes such as E. coli polymerase I Klenow fragment
  • sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis is provided as a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained.
  • recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants.
  • a polyclonal antibody is prepared by immunizing an animal with an immunogenic composition in accordance with the present invention and collecting antisera from that immunized animal.
  • an immunogenic composition in accordance with the present invention
  • a wide range of animal species can be used for the production of antisera.
  • the animal used for production of anti-antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a goat. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.
  • a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a carrier.
  • exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers.
  • KLH keyhole limpet hemocyanin
  • BSA bovine serum albumin
  • Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers.
  • Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m -maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine.
  • the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants.
  • adjuvants include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis ), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.
  • the amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization.
  • a variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal).
  • the production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster, injection may also be given. The process of boosting and titering is repeated until a suitable titer is achieved.
  • the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate mAbs.
  • mAbs may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265 .
  • this technique involves immunizing a suitable animal with a selected immunogen composition, e . g ., a purified or partially purified LCRF protein, polypeptide or peptide.
  • the immunizing composition is administered in a manner effective to stimulate antibody producing cells.
  • Rodents such as mice and rats are preferred animals, however, the use of rabbit, sheep frog cells is also possible.
  • the use of rats may provide certain advantages (Goding, 1986), but mice are preferred, with the BALB/c mouse being most preferred as this is most routinely used and generally gives a higher percentage of stable fusions.
  • somatic cells with the potential for producing antibodies, specifically B-lymphocytes (B-cells), are selected for use in the mAb generating protocol.
  • B-cells B-lymphocytes
  • These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible.
  • a panel of animals will have been immunized and the spleen of animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe.
  • a spleen from an immunized mouse contains approximately 5 ⁇ 10 7 to 2 ⁇ 10 8 lymphocytes.
  • the antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized.
  • Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render then incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).
  • any one of a number of myeloma cells may be used, as are known to those of skill in the art (Goding, 1986; Campbell, 1984).
  • the immunized animal is a mouse
  • P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions.
  • NS-1 myeloma cell line also termed P3-NS-1-Ag4-1
  • P3-NS-1-Ag4-1 Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line.
  • Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 ratio, though the ratio may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes.
  • Fusion methods using Sendai virus have been described (Kohler and Milstein, 1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter et al ., (1977).
  • PEG polyethylene glycol
  • the use of electrically induced fusion methods is also appropriate (Goding, 1986).
  • Fusion procedures usually produce viable hybrids at low frequencies, about 1 ⁇ 10 -6 to I ⁇ 10 -8 . However, this does not pose a problem, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that would normally continue to divide indefinitely) by culturing in a selective medium.
  • the selective medium is generally one that contains an agent that blocks the de novo synthesis of nucleotides in the tissue culture media.
  • Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block de novo synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis.
  • the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium).
  • HAT medium a source of nucleotides
  • azaserine the media is supplemented with hypoxanthine.
  • the preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium.
  • the myeloma cells are defective in key enzymes of the salvage pathway, e.g. , hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive.
  • HPRT hypoxanthine phosphoribosyl transferase
  • the B-cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B-cells.
  • This culturing provides a population of hybridomas from which specific hybridomas are selected.
  • selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity.
  • the assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.
  • the selected hybridomas would then be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide mAbs.
  • the cell lines may be exploited for mAb production in two basic ways.
  • a sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion.
  • the injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid
  • the body fluids of the animal such as serum or ascites fluid, can then be tapped to provide mAbs in high concentration.
  • the individual cell lines could also be cultured in vitro , where the mAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations.
  • mAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography.
  • compositions disclosed herein are for oral administration, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet
  • the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between 2 to 60% of the weight of the unit.
  • the amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like: a lubricant, such as magnesium stearate: and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil ofwintergreen, or cherry flavoring.
  • a binder as gum tragacanth, acacia, cornstarch, or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like:
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or
  • any material may be present as coatings or to otherwise modify the physical form of the dosage unit.
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup of elixir may contain the active compounds sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compounds may be incorporated into sustained-release preparation and formulations.
  • the active compounds may also to be administered parenterally or intraperitoneally.
  • Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanoL polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • a coating such as lecithin
  • surfactants for example, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • compositions that do not produce an allergic or similar untoward reaction when administered to a human.
  • pharmaceutically acceptable refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.
  • aqueous composition that contains a protein as an active ingredient is well understood in the art.
  • such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.
  • the preparation can also be emulsified.
  • composition can be formulated in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.
  • aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580).
  • B. burgdorferi strains B31 (ATCC 35210), Sh-2-82, and N40 were originally isolated from Ixodes scapularis ticks in the state of New York (Burgdorfer et al ., 1982; Schwan et al ., 19886; Barthold et al ., 1990). These strains have been shown to be infectious in laboratory animals (Barthold et al ., 1990; Norris et al ., 1995).
  • the high-passage B31 strain (ATCC 35210) had undergone in vitro passages for several years and had lost infectivity (Moody et al ., 1990).
  • the resultant DNA mixture was ligated into Bam HI-digested pBluescript II SK (-) vector (Stratagene).
  • the ligation mixture was used to transform E. coli XL-1 blud MRF' competent cells (Stratagene) and the transformants were plated on Luria-Bertani (LB) agar containing 100 ⁇ g/ml ampicillin, 0.5 mM isopropyl thiogalactopyranoside, and 20 ⁇ g/ml 5-bromo-4-chloro-3-indolyl-D-galactoside.
  • LB broth cultures inoculated with white colonies were blotted to Hybond-N + nylon membranes (Amersham, Arlington Heights, IL) with a Bio-Dot apparatus (Bio-Rad, Hercules, CA) and screened by hybridization with [ 32 P]-labeled driver and target DNA.
  • the clones that hybridized only to target probe but not to driver probe were partially sequenced using vector sequence-based T3 and T7 primers.
  • Total B. burgdorferi DNA was prepared in agarose inserts and separated in 1% Fastlane agarose gels (FMC, Rockland, ME) by pulsed-field electrophoresis as described previously (Norris et al ., 1995). Restriction enzyme-digested DNA fragments were separated by standard agarose gel electrophoresis (Sambrook et al ., 1989). DNA bands were visualized by ethidium bromide staining. For Southern hybridization, DNA was blotted to Hybone-N + nylon membranes by the alkaline transfer method (Sambrook et al ., 1989).
  • the blots were hybridized with [ 32 P]-labeled probes at 65°C in the presence of 1M NaCl overnight as described previously (Walker et al ., 1995). The blots were washed sequentially as follows: once in 2X SSC at 65°C for 15 min, twice in 1X SSC at 65°C for 15 min, and twice in 0.1X SSC at room temperature for 10 min. Autoradiography was performed using X-OMAT film (Kodak, Rochester, NY) with enhancing screens.
  • the total plasmid DNA of B31-5A3 was prepared and treated with mung bean nuclease to open the covalently linked telomeres of the linear plasmids as described by Hinnebusch et al. (1990).
  • the resulting plasmid DNA was filled in with the Klenow fragment of DNA polymerase, and an Eco RI linker (5'-CCGGAATTCCGG-3') was ligated onto the plasmid ends using T4 ligase.
  • the preparation was then digested with EcoRI and ligated into EcoRI-treated ⁇ DASH II vector (Stratagene).
  • the recombinant phages were propagated and screened by plaque hybridization with the pJRZ53 probe according to the vector manufacturer's instructions. Lambda phage DNA was purified by CsCI gradient purification method (Sambrook et al ., 1989).
  • the purified bacteriophage DNA was treated with DNase I in the presence of Mn ++ and cloned into Eco RV-digested pBluescript II SK (-) as described previously (Demolis et al ., 1995).
  • the insert DNA of ⁇ DASH-Bb12 was excised from agarose gels, purified using a Qiaex II gel extraction kit (Qiagen, Chatsworth, CA), radiolabeled, and used as a probe to screen E. coli XL1-blue MRF' transformants by Southern hybridization. Positive clones were sequenced as described below using T3 and T7 primers.
  • sequenced regions were filled in by primer walking.
  • sequenced fragments were assembled using by the GELASSEMBLE program of GCG (Program Manual for the Wisconsin Package, Version 8. Genetics Computer Group, Madison. WI). High stringency settings were applied to discriminate identical sequences from highly homologous sequences.
  • PCRTM amplifications were performed using the thermalase PCRTM kit (Amresco, Solon, OH) in a Minicycler from MJ Research (Watertown, MA).
  • a two-step program was used as follows: 96°C for 3 min, 5 cycles of denaturation at 95°C for 40 sec, annealing at 56°C for 40 sec, and extension at 72°C for 2 min, followed by 30 cycles at a higher annealing temperature at 65°C.
  • RNA was extracted from late log-phase cultures of B. burgdorferi B31-5A3 with a RNA purification kit (Amresco). The resulting RNA preparation was used to produce cDNA with the R4066 primer (5'-CTTTGCGAACGCAGACTCAGCA-3') ( FIG. 2C ), primer R4066, and 1 ⁇ l of the RT reaction were used for PCRTM reaction as described above to produce an 198-bp fragment. The PCRTM product was then cloned into the pCR-II vector (Invitrogen, San Diego, CA) according to the supplier's manual, and the resulting clones were sequenced.
  • pCR-II vector Invitrogen, San Diego, CA
  • a 614-bp fragment containing the vls1 cassette was amplified by PCRTM using (+) strand primer F4120 (S'- GCGGATCC AGTACGACGGGGAAACCAG-3') and (-) strand primer R4121 (5'- GCGGATCC CCTTCTCTTTCTCACCATCC-3') ( FIG. 2C ).
  • the inventors' added a 8-bp sequence (underlined) at the 5'-ends of both primers to create Bam HI sites.
  • the resultant PCRTM products containing the entire vls1 cassette region was cloned into the Bam HI site of the pGEX-2T expression vector (Pharmacia, Piscataway, NJ) to produce a GST fusion protein (Designated GST-Vls1) in E. coli strain BL-21(DE3) according to the supplier's instructions.
  • the insert sequence of the recombinant plasmid was verified prior to use for protein expression.
  • the fusion protein was purified by glutathione-Sepharose 4B column (Pharmacia) according to the manufacturer's instructions.
  • Antisera against the GST-Vls1 fusion protein and GST as a control were prepared in rabbits by immunization of rabbits with 20 ⁇ g protein in complete Freunds adjuvant and boosting with the same amount of protein in incomplete Freunds adjuvant at 3-week intervals (Sambrook et al ., 1989). Nonspecific reactivity of the antiserum was removed by absorption with cell lysate of a low-infectivity B31 clone 5A2 lacking pBB28La plasmid ( FIG. 1B ) as described previously (Carroll and Gherardini, 1996). Antiserum against recombinant OspD was prepared in a similar manner, and monoclonal antibody H9724 reactive with B. burgdorferi flagellum protein (Fla) was obtained as a hybridoma culture supernatant by D.D. Thomas (University of Texas Health Science Center at San Antonio).
  • Late log-phase B. burgdorferi cultures were harvested by centrifugation and washed in phosphate-buffered-saline (PBS, 135 mM NaCl, 9 mM Na 2 HPO 4 , 6 mM KH 2 PO 4 , pH 7.2). The organisms were resuspended at a concentration of 10 10 cells/ml in PBS. Proteins of approximately 10 7 organisms were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), electro-transferred to PVDF membranes (Millipore, Bedford, MA), and detected with antibody using a ECL western blot kit from Amersham according to the supplier's instructions.
  • PBS phosphate-buffered-saline
  • SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
  • Proteinase K digestion of B. burgdorferi B31-5A3 was performed as described previously (Norris et al ., 1992). Proteins of the treated organisms were separated by SDS-PAGE, electro-transferred to PVDF nitrocellulose, and reacted with antisera against GST-Vls1 or OspD or with monoclonal antibody H9724. Reactions were visualized using the ECL western blot kit.
  • the original stock of B31-5A3 (Norris et al ., 1995) was cultured in BSK II broth for 7 days, and the culture was diluted to a concentration of 10 6 cells/ml in BSK II broth.
  • One hundred microliters of the diluted culture (10 5 organisms) were used to inoculate each of eight 3-week-old female C3H/HeN mice by intradermal injection at the base of the tail. Each mouse was implanted with an identification microchip for follow-up samplings during the course of infection.
  • the organisms were isolated by inoculating 50 ⁇ l of blood or a full-thickness biopsy ( ⁇ 2 mm in diameter) of the ear into 6 ml of BSK II broth.
  • FIG. 8 A flow diagram is provided in FIG. 8. Ear punch biopsies ⁇ 2mm in diameter were obtained from 5 of 8 mice. The cultures were named according to their source (i . e . m1e4 refers to mouse 1, ear culture, 4 weeks). Clonal populations were obtained by plating on passage of culture BSKY agar plates, and 12 colonies of each isolate were selected, cultured briefly in 2ml BSKY medium, and frozen. Individual clones were designated m1e4A, m1e4B, etc . Samples of these clones were subjected to amplification of the vls cassette present in the vls E expression site by using primers in the "constant" regions on either side of the cassette. The resulting PCRTM products were sequenced directly.
  • Each one of the mouse isolate sequences appeared to be comprised of a mosaic of segments from several different silent vls cassettes (between 7 and 11 in preliminary analyses). Sequence variability was restricted to the vls cassette region delimited by the ' sequences, and in all cases the open reading frame was preserved.
  • the vlsE cassette regions of controls consisting of five clonal populations from the inoculating culture were identical to the original vls1 sequence, as were the sequences obtained from cultures passed 2 to 4 times in vitro (one week per passage). Therefore the rearrangement process appears to be activated in vivo, and does not occur at a rapid rate in vitro .
  • B. burgdorferi strains generally exhibit loss of infectivity following 10 to 17 in vitro passages (Johnson et al ., 1984; Schwan et al ., 1988a; Norris et al ., 1995), coinciding with the loss of plasmids (Barbour, 1988; Xu et al ., 1996). It was hypothesized that the decreased infectivity occurring during in vitro passage of Lyme disease Borreliae is due to loss of genetic content, specifically plasmids encoding virulence factors. Therefore, the inventors' expected to identify some of these virulence factors by directly comparing the plasmid content of the organisms differing in infectivity.
  • the inventors' utilized a simple subtractive hybridization technique to enrich and eventually identify sequences present only in high-infectivity organisms.
  • Total DNA from a high-infectivity (low-passage) B31 strain was digested to completion with Sau 3AI (target DNA).
  • the target DNA was mixed with a 50-fold excess of total DNA from a low-infectivity (high passage) B31 derivative that had been sheared by ultrasonication (driver DNA).
  • the DNA mixture was denatured and allowed to reanneal. DNA fragments in the resultant DNA preparation in which the Sau 3 AI sites were regenerated were ligated into the Bam HI site of pBluescript SK (-).
  • a total of 63 clones were isolated and screened by Southern hybridization using the target DNA and driver DNA as probes, respectively. Eight of these clones hybridized with target DNA but not to driver DNA.
  • the inserts of the eight clones were partially sequenced using the vector-based primers, and the sequences were subjected to database searches for sequence similarity.
  • One of the clones designated pJRZ53, contained a 562-base pair (bp) Sau 3 AI fragment with a single, contiguous open reading frame. The predicted amino acid sequence of this open reading frame was compared to Vmps of B. hermsii, and showed 27.2% identity and 56.8% similarity to Vmp17. Based on this sequence similarity, the pJRZ53 insert was called a vmp -like sequence ( vls ). The pJRZ53 insert exhibited a lower degree of amino acid sequence similarity with B. burgdorferi B31 outer surface protein C (OspC) (26.6% identity and 44.5% similarity).
  • the pJRZ53 insert was hybridized with Southern blots of total B31 DNA separated by pulsed-field electrophoresis.
  • a DNA band migrating at 28 kb hybridized to the probe (see FIG. 1B ) and was determined to be a linear plasmid by two-dimensional agarose gel electrophoresis and restriction mapping.
  • This vls -containing plasmid of B. burgdorferi B31 was designated pBB28La.
  • B31-5A3 A particular clonal population of B. burgdorferi B31 (clone B31-5A3) was utilized in order to minimize clonal variation.
  • B31-5A3 has a high-infective phenotype (Norris et al ., 1995) and possesses the pBB28La plasmid ( FIG. 1B , lane 3).
  • pJRZ53 was shown to hybridize with a single 14-kb fragment generated by digestion of B31-5A3 plasmid DNA with Eco RI.
  • the 14-kb Eco RI fragment was cloned into ⁇ DASHII to permit a detailed analysis of this region.
  • the 14-kb fragment was predicted to have a covalently-closed telomere at one end Therefore, a technique developed by Hinnebusch et al . (1992) was utilized to open the telomeric loop with mung bean nuclease and attach an Eco RI linker, thereby permitting ligation into the cloning vector.
  • a lambda clone, designated ⁇ DASH-Bb12 was isolated that contained the 14-kb B. burgdorferi DNA fragment, as confirmed by restriction and hybridization.
  • An internal Eco RI site was found to divide the ⁇ DASH-Bb12 insert into two smaller 4- and 10-kb fragments; an independently-derived clone containing the 10-kb fragment was also isolated during screening of the library.
  • the region containing the internal Eco RI site was amplified using B. burgdorferi B31-5A3 DNA as the template.
  • the resulting PCRTM product had a sequence identical to that of the corresponding region of ⁇ DASH-Bb12, indicating that the 4- and 10-kb Eco RI fragments are contiguous in pBB28La. Restriction digestion of B.
  • a random cloning, "shotgun" strategy was utilized to sequence nearly 10 kb of the ⁇ DASH-Bb12 insert.
  • a total of 80 random clones were sequenced using vector-based primers. Additional sequencing reactions were carried out to fill the gaps between the sequenced regions by primer-walking. The resulting assembled sequences had an average of 5-fold coverage.
  • a short segment ( ⁇ 200 bp) 1227 bp from the right telomeric end has been refractory to sequencing by a number of techniques.
  • the vls locus has a G+C content of 50%.
  • the sequence data revealed an extensive vls locus within the 10-kb Eco RI fragment consisting of an expression site (designated vlsE ) and 15 vls cassettes that are highly homologous to the central portion of vlsE (SEQ ID NO:1 and SEQ ID NO:3).
  • the presence of the Eco RI linker sequence between the insert DNA and the vector sequence defined the location of the right telomeric end.
  • VlsE is located 82 bp from the right telomere of pBB28La. It possesses two unique sequences at each of the 5' and 3' regions and a 570-bp vls cassette in the middle which was designated as the vls1 cassette ( FIG. 2B ).
  • the vls1 cassette is flanked at either end by the 17-bp direct repeat sequence 5'- GAGGGGGCTATTAAGGA -3' (SEQ ID NO:8) encoding the amino acids EGAIK.
  • An array of 15 vls cassettes begins approximately 500 bp upstream of vlsE on the same plasmid ( FIG. 2A ).
  • the vls1 cassette and the other vls cassettes ( vls2 through vls16 ) share 90.0% to 96.1% nucleotide sequence identity and 76.9% to 91.4% predicted amino acid sequence identity.
  • the 17-bp direct repeat is conserved in nearly all of the upstream vls cassette sequences.
  • VlsE gene of B. burgdorferi B31-5A3 is predicted to encode a 356 amino acid protein with a molecular mass of 35,986 daltons ( FIG. 2C ).
  • a consensus ribosome binding site and consensus -35 and -10 sigma -70-like promoter sequences are located upstream of the predicted translational start site.
  • VlsE contains a putative lipoprotein leader sequence with an apparent signal peptidase II cleavage site (FINC) (Wu and Tokunaga, 1986) which resembles those of other Borrelial lipoproteins, including OspC (Fuchs et al ., 1992).
  • VlsE shows 37.4% identity and 57.8% similarity homology at the amino acid level and 58.8% identity at the nucleotide level to vmp17 of B. hermsii ( FIG. 3A ).
  • VlsE shares a lower level of homology to B . burgdorferi ospC at both the nucleotide (41.6% identity) and amino acid (26.3% identity and 47.5% similarity) levels.
  • the particular vlsE allele contained in B. burgdorferi B31 clone 5A3 has been designated vlsE1, to distinguish it from variant vlsE alleles.
  • vls cassettes (474 to 594 bp in length) were identified ⁇ 500 bp upstream of vlsE ( FIG. 2A and FIG. 3B , SEQ ID NO:1 and SEQ ID NO:3). These cassettes are oriented in the opposite direction to vlsE and are arranged in a head-to-tail fashion in a nearly contiguous open reading frame interrupted only by a stop codon in cassette vls11 and two frame shifts in cassettes vls14 and vls16. None of these vls cassettes have recognizable ribosome binding sites or promoter sequences; therefore they are thought to be nonexpressed or 'silent'.
  • the ends of the vls cassettes were defined by alignment with the vlsl cassette ( FIG. 3B ).
  • the vls cassettes have the same 17-bp direct repeat at either end; one exception is the joint region between vls9 and vls10, where only 10 identical nucleotides were identified.
  • the first vls cassette (vls2) lacks the first 126 bp of the vls cassette sequence, but contains a 55-bp sequence which is identical to the 5' region of vlsE , coding for the last I 1 amino acids of the leader peptide and the first 7 amino acids of the putative mature VlsE.
  • the vls7 cassette contains a 105-bp deletion relative to vls1 in the 5' region.
  • the vls8 and vls10 cassettes are lacking the first 54 nucleotides of the cassette.
  • the last cassette in this array, vls16 is truncated at the 3' end and is followed by an apparent noncoding region.
  • the 562-bp insert of pJRZ53 was localized to the joining region between vls8 and vls9 by sequence comparison.
  • the vls cassettes contain six highly conserved regions which are interspersed by six variable regions (VR) at both the nucleotide and amino acid levels.
  • FIG. 3B shows an alignment of the predicted amino acid sequences for all 16 vls cassettes identified. Except for occasional codon changes and the deletions mentioned previously, the conserved regions are almost identical in all cassettes.
  • the vls cassettes are distinguished from each other by considerable sequence variations limited predominantly to the six variable regions (VR-I through VR-VI). The variable regions range from 21 bp (VR-VI) to 63 bp (VR-IV) in length.
  • variable sequences in VR-I are interspersed by stretches of identical sequences ranging from 6 to 9 bp, as reflected in the predicted amino acid sequences ( FIG. 3B ).
  • RT-PCRTM reverse transcriptase-polymerase chain reaction
  • an internal 614-bp fragment containing vls1 was amplified by polymerase chain reaction (PCRTM) and cloned into the pGEX-2T expression vector to produce a glutathione-S-transferase (GST)-Vls1 fusion protein in E. coli .
  • PCRTM polymerase chain reaction
  • GST-Vls1 fusion protein was used to probe protein blots of B. burgdorferi B31-5A2 and B31-5A3 clones.
  • the low-infectivity clone B31-5A2 was used as a negative control for immunoblot analysis, because it lacks pBB28La ( FIG. 1B , lane 2).
  • the antiserum detected a protein with an M, of approximately 45,000 daltons in the high-infectivity clone B31-5A3 but not in the low-infectivity clone B31-5A2 ( FIG. 6 , lanes 10 and 11). Neither the preimmune serum nor antiserum against GST alone reacted with this protein.
  • the size of the protein identified by immunoblot analysis is larger than the predicted molecular mass of 33,956 daltons. Attachment of a lipid moiety to the N-terminus of VlsE by signal peptidase II may contribute to the altered electrophoretic mobility.
  • VlsE Exposure of viable B. burgdorferi 5A3 to proteinase K produced results consistent with the surface localization of VlsE.
  • VlsE was degraded by proteinase K in as little as 10 min ( FIG. 4A ), even though the organisms appeared intact by dark-field microscopy.
  • B. burgdorferi OspD protein was also removed by proteinase K treatment ( FIG. 4B ).
  • the Fla subunit of the periplasmic flagella was not affected by proteinase K ( FIG. 4C ), providing further evidence that the outer membranes of the organisms remained intact during the proteinase K treatment.
  • FIG. 5A The overall experimental design is illustrated in FIG. 5A .
  • B. burgdorferi B31-5A3 inoculated directly from a frozen stock, was cultured for seven days and used to intradermally inject a group of eight female C3H/HeN mice (10 5 organisms per mouse). B. burgdorferi was re-isolated four weeks after the initial infection. To retain the infected mice for multiple samplings at different periods of infection, only ear punch biopsy and blood specimens were taken to culture the organisms.
  • a total of five ear and six blood isolates were examined.
  • 16 B. burgdorferi clones of each isolate were obtained by colony formation on agarose plates and preserved by freezing.
  • One clone from each of the isolates was used as a source of template DNA to amplify the expressed vls cassette sequence using primers F4120 and R4066 specific for the 5' and 3' unique regions of vlsE , respectively ( FIG. 2C ).
  • the first passage frozen stock was used to provide DNA template for PCRTM amplification to avoid possible variation during in vitro culture.
  • the PCRTM products were sequenced directly using the same set of primers.
  • burgdorferi clones and associated sequences derived from the 4-week isolates were designated by a combination of mouse number (m1 to m8), tissue source (e for ear and b for blood), week post infection (4), and a clone designation (A to P) for the 16 clones from each isolate.
  • the m1e4A and m5e4A alleles have VR-I and VR-II identical to vls4, whereas the VR-I and VR-III regions of m6b4A are identical to the same regions of vls10 ( FIG. 5B ).
  • the VR-IV and VR-V regions of mle4A appear to be hybrids of portions of vls10 and vls5 and vls3 and vls5, respectively. Similar patterns can also be found in the rest of these vlsE alleles. These observations suggested that segments, but not entire regions, of the silent vls cassettes were recombined into the expression site. Comparison to the silent cassette sequences at the nucleotide level suggested that 6 to 11 separate recombination events occurred in each of the clones isolated from mice 4 weeks post inoculation. This type of combinatorial reactions could potentially result in millions of different vlsE alleles.
  • Each of these clones again contained a unique combination of sequences identical to portions of several silent vls cassettes,
  • m1e4C contained VR-1 of vls12 , VR-II of vls4 , VR-III of vls8 , and VR-IV and VR-VI of vls11 .
  • the homogeneous nature of B. burgdorferi clones derived from the blood isolate of mouse 1 may be due to the presence of relatively few organisms in the blood as compared to ear biopsies, resulting essentially in cloning by limiting dilution.
  • selection imposed by the host immune response in different tissue environments may affect diversity of vlsE variants.
  • sequence variations in the clonal populations of the mouse isolates may also arise from background heterogeneity of the stock culture of the clone B31-5A3 occurring during in vitro culture, because the original clone was cultured 7 days prior to the inoculation of C3H/HeN mice.
  • the stock culture of B31-5A3 was inoculated into BSK II medium and cultured sequentially in two in vitro passages of 7 days (14 days total).
  • PCRTM products amplified from the vlsE cassette region were obtained using a sample of this culture as template and either sequenced directly or cloned into the PCRTM II vector and sequenced.
  • the mouse isolates containing m1b4A and m3b4A alleles had bands which were weakly reactive with the antiserum ( FIG. 6 , lanes 2 and 5).
  • the other clones examined exhibited faint bands that were visible only with a longer chemiluminescent exposures of the membrane. These reactive bands migrated at lower M r s than VlsE expressed by the parental clone B31-5A3. indicative of changes in either size or conformation. No reactive bands were observed in clone B31-5A2, which lacks the pBB28La plasmid.
  • the decreased reactivity of mouse isolates with antiserum against the parental Vls1 cassette region indicated that the sequence differences in these VlsE variants ( FIG. 5B ) resulted in changes in important cassette region epitopes and hence antigenic variation.
  • Sera from the mice in experiments outlined in FIG. 5A were tested for reactivity with VlsE as a means of determining whether this protein is expressed in vivo. Serum obtained from mouse 1 on 28 days post inoculation with B31-5A3 was reacted with immunoblots of 5A3 (expressing VlsE), 5A2 (lacking vlsE), the GST-Vls1 fusion protein, GST as a control, and two clones isolated from mouse 1 on day 28 (M1e4A and M1b4A). The results shown in FIG 6C indicated that the C3H/HeN mice infected with B. burgdorferi mounted a strong antibody response to VlsE.
  • the prebleed serum of mouse 1 had no detectable reactivity
  • the serum sample collected from the same mouse 4 weeks after initial infection with B. burgdorferi B31-5A3 reacted strongly with the GST-Vls1 fusion but not with GST alone, indicating expression of VlsE in the mammalian host.
  • the same serum also had a strong reactivity with the VlsE protein of B. burgdorferi B31-5A3, whereas no detectable VlsE band was observed with B. burgdorferi B31-5A2.
  • the VlsE variant Mle4A exhibited decreased reactivity when reacted with the same mouse serum as shown in FIG. 6C .
  • FIG. 6E A representative serum sample from a clinically diagnosed patient with early Lyme disease symptoms contained highly reactive antibody against the VlsE protein of B31-5A3 and GST-Vls1 fusion protein ( FIG. 6E ). Similar to the serum from the C3H/HeN mouse ( FIG. 6C ), the sera from the Peromyscus leucopcus mouse ( FIG. 6D ) and the Lyme disease patient ( FIG. 6E ) had little reactivity to the VlsE variant M1e4A.
  • VlsE is expressed and is highly immunogenic in the mammalian host, but that genetic variation may generate unique VlsE variants which are no longer fully recognized by the immune response against the parental VlsE. They also indicate that antibodies generated against VlsE may be useful in immunodiagnosis of Lyme disease.
  • VlsE is expressed and is highly immunogenic in the mammalian host, but that genetic variation can generate unique VlsE variants which are no longer fully recognized by the immune response against the parental VlsE. Additional experiments have shown that some sera from Lyme disease patients also have reactivity with the GST-Vls1 fusion protein and VlsE of B. burgdorferi B31-5A3, but not with some of the VlsE variants, thus further supporting the expression and antigenic variation of VlsE in vivo . TABLE 5 Correlation of pBB28La with Infectivity Strain Strains containing pBB28La/total strains tested High-infectivity phenotype Low-infectivity phenotype B.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Claims (17)

  1. Ein isoliertes immunogenes Polypeptid, das
    a) zumindest 85 % Homologie zur Aminosäuresequenz von SEQ ID Nr.: 2 aufweist; und
    b) spezifisch mit Antikörpern bindet, die gegen ein Polypeptid mit der Aminosäuresequenz von SEQ ID Nr.: 2 erzeugt wurden.
  2. Ein isoliertes Nukleinsäure-Segment, umfassend
    a) die Nukleinsäuresequenz von SEQ ID Nr.: 1; oder
    b) das Komplement von (a).
  3. Das Nukleinsäure-Segment von Anspruch 2, wobei besagtes Nukleinsäure-Segment 2.000 Basen lang ist.
  4. Das Nukleinsäure-Segment von Anspruch 2, wobei besagtes Nukleinsäure-Segment 3.000 Basen lang ist.
  5. Das Nukleinsäure-Segment von Anspruch 2, wobei besagtes Nukleinsäure-Segment 5.000 Basen lang ist.
  6. Das Nukleinsäure-Segment von Anspruch 2, wobei besagtes Nukleinsäure-Segment 8.000 Basen lang ist.
  7. Ein Verfahren zur Verwendung eines DNA-Segments gemäß irgendeinem der Ansprüche 2 bis 6, um ein Polypeptid zu erzeugen, wobei das Verfahren folgendes umfasst:
    a) Herstellen eines rekombinanten Vektors, in dem ein DNA-Segment von irgendeinem der Ansprüche 2 bis 6 unter der Kontrolle eines Promotors positioniert ist;
    b) Einbringen des besagten rekombinanten Vektors in eine Wirtszelle;
    c) Kultivieren von besagter Wirtszelle unter Bedingungen, die die Expression des Polypeptids ermöglichen; und
    d) Sammeln des besagten exprimierten Polypeptids.
  8. Ein isoliertes immunogenes Polypeptid, kodiert durch eine Nukleinsäure gemäß irgendeinem der Ansprüche 2 bis 6.
  9. Das Polypeptid gemäß Anspruch 8, des weiteren definiert als ein isoliertes Polypeptid, das spezifisch mit Antikörpern bindet, die gegen ein Polypeptid erzeugt wurden, das zumindest die Aminosäuresequenz von SEQ ID Nr.: 2 aufweist.
  10. Eine Proteinzusammensetzung, umfassend das Polypeptid von Anspruch 8 oder 9.
  11. Die Zusammensetzung von Anspruch 10, des weiteren vorliegend umfasst in einem physiologisch verträglichen Arzneistoffträger.
  12. Eine Zusammensetzung von Anspruch 10 oder 11 zur Verwendung in einem Verfahren zum Erzeugen einer Immunantwort, umfassend eine pharmazeutische Zusammensetzung, die eine immunologische effektive Menge von besagter Zusammensetzung umfasst, wobei die Zusammensetzung geeignet ist, einem Subjekt verabreicht zu werden.
  13. Ein aufgereinigter Antikörper, der spezifisch an das Polypeptid von Anspruch 9 bindet.
  14. Der Antikörper von Anspruch 13, wobei der Antikörper mit einem nachweisbaren Label verknüpft ist.
  15. Ein in-vitro-Verfahren zum Diagnostizieren der Lyme-Erkrankung, umfassend das Untersuchen einer Probe eines Subjekts auf das Vorliegen eines Nukleinsäure-Segments gemäß irgendeinem der Ansprüche 2 bis 6, eines Polypeptids von Anspruch 8 oder 9 oder eines Antikörpers, der immunologisch an ein Polypeptid von Anspruch 9 bindet.
  16. Ein in-vitro-Verfahren zum Nachweis einer Borrelia-Infektion, umfassend:
    (a) Erhalten eines Antikörpers, der immunologisch an ein Polypeptid von Anspruch 9 bindet, oder eines Polypeptids, das immunologisch an solch einen Antikörper bindet;
    (b) Vermischen einer Probe, erhalten von einem Subjekt, und des Antikörpers oder Polypeptids; und
    (c) Bestimmen, ob immunologisches Binden zwischen den Antikörper und einem Polypeptid in der Probe auftritt, oder zwischen dem Polypeptid und einem Antikörper in der Probe;
    wobei das immunologische Binden ein Hinweis auf die Borrelia-Infektion ist.
  17. Ein Immunodetektionskit, umfassend, in einem geeigneten Container, ein oder mehrere Polypeptide gemäß irgendeinem der Ansprüche 8 bis 9, oder einen Antikörper, der an ein Polypeptid gemäß irgendeinem der Ansprüche 8 bis 9 bindet, sowie ein Immunodetektions-Agens.
EP97914794A 1996-02-21 1997-02-20 Vmp-ähnliche sequenzen von pathogener borrelia Expired - Lifetime EP0894143B2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE69733944T DE69733944T3 (de) 1996-02-21 1997-02-20 Vmp-ähnliche sequenzen von pathogener borrelia
EP05010338.1A EP1589109B1 (de) 1996-02-21 1997-02-20 VMP-ähnliche Sequenzen von Pathogener Borrelia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1202896P 1996-02-21 1996-02-21
US12028P 1996-02-21
PCT/US1997/002952 WO1997031123A1 (en) 1996-02-21 1997-02-20 Vmp-like sequences of pathogenic borrelia

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP05010338.1A Division EP1589109B1 (de) 1996-02-21 1997-02-20 VMP-ähnliche Sequenzen von Pathogener Borrelia
EP05010338.1 Division-Into 2005-05-12

Publications (4)

Publication Number Publication Date
EP0894143A1 EP0894143A1 (de) 1999-02-03
EP0894143A4 EP0894143A4 (de) 2001-06-13
EP0894143B1 EP0894143B1 (de) 2005-08-10
EP0894143B2 true EP0894143B2 (de) 2012-04-18

Family

ID=21753038

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97914794A Expired - Lifetime EP0894143B2 (de) 1996-02-21 1997-02-20 Vmp-ähnliche sequenzen von pathogener borrelia
EP05010338.1A Revoked EP1589109B1 (de) 1996-02-21 1997-02-20 VMP-ähnliche Sequenzen von Pathogener Borrelia

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05010338.1A Revoked EP1589109B1 (de) 1996-02-21 1997-02-20 VMP-ähnliche Sequenzen von Pathogener Borrelia

Country Status (7)

Country Link
US (11) US6437116B1 (de)
EP (2) EP0894143B2 (de)
AT (1) ATE301716T1 (de)
AU (1) AU2191597A (de)
DE (1) DE69733944T3 (de)
DK (1) DK0894143T4 (de)
WO (1) WO1997031123A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0894143B2 (de) 1996-02-21 2012-04-18 Board Of Regents, The University Of Texas System Vmp-ähnliche sequenzen von pathogener borrelia
CN1261896A (zh) 1997-06-30 2000-08-02 杜雷安教育基金会行政处 诊断和预防莱姆病用的组合物的表面抗原和蛋白质
US6475492B1 (en) * 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
AU2003223244A1 (en) * 2002-03-11 2003-09-29 The Johns Hopkins University Molecular switches and methods for making and using the same
AU2003299872A1 (en) 2002-12-20 2004-07-22 Board Of Regents, The University Of Texas System Vmp-like sequences of pathogenic borrelia species and strains
US7149014B2 (en) * 2003-04-18 2006-12-12 California Institute Of Technology Holographic memory using beam steering
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US7693299B2 (en) * 2004-01-13 2010-04-06 New York University Method, system, storage medium, and data structure for image recognition using multilinear independent component analysis
US8338138B2 (en) * 2004-01-28 2012-12-25 The John Hopkins University Methods for making and using molecular switches involving circular permutation
WO2007133623A2 (en) * 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
KR101336248B1 (ko) * 2007-02-22 2013-12-03 삼성전자주식회사 홀로그래픽 저장 매체에의 데이터 기록 장치 및 방법
TR201000668T1 (tr) * 2007-07-31 2010-06-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
US8313915B2 (en) * 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
JP2013511530A (ja) * 2009-11-17 2013-04-04 アバクシス， インコーポレイテッド ライム病抗体の検出のためのペプチドおよび方法
WO2011112805A2 (en) * 2010-03-10 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Compositions and methods for screening for lyme disease
US8624338B2 (en) * 2011-05-05 2014-01-07 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-nanometer-projection apparatus for lithography, oxidation, inspection, and measurement
US10100092B2 (en) 2011-11-03 2018-10-16 Vca, Inc. Compositions and methods to detect various infectious organisms
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
WO2016049148A1 (en) 2014-09-24 2016-03-31 Wellstat Diagnostics, Llc Compositions and methods for te diagnosis of lyme disease
US11131670B2 (en) 2015-08-27 2021-09-28 Quidel Corporation Immunoassay test device with two fluid flow paths for detection and differentiation of two or more analytes
US10401358B1 (en) 2016-09-30 2019-09-03 Ross Southern Laboratories Serodiagnosis of lyme disease by use of two recombinant proteins in ELISA
CN110573880B (zh) 2017-02-10 2023-05-16 奎多公司 具有受控流体流动通道的基底的横向流动测试
US20200255889A1 (en) * 2017-09-25 2020-08-13 The Trustees Of Columbia University In The City Of New York Serological assay for detection of exposure to and infection by tick-borne pathogens
KR20230154223A (ko) * 2021-03-02 2023-11-07 아이덱스 래보러토리즈, 인코포레이티드 에폭시-기반 수지에 부착된 생화학적 프로브

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1202896A (en) 1916-03-14 1916-10-31 Frank C Ronk Steam-radiator.
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US4801540A (en) 1986-10-17 1989-01-31 Calgene, Inc. PG gene and its use in plants
US5246844A (en) 1991-10-22 1993-09-21 Board Of Regents, The University Of Texas System Virulence associated proteins in borrelia burgdorferi (bb)
US5217874A (en) 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5385826A (en) 1989-04-21 1995-01-31 Gundersen Medical Foundation, Ltd. Diagnostic assay for lyme disease
US5279938A (en) 1989-06-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services Sensitive diagnostic test for lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5187065A (en) 1989-12-22 1993-02-16 Schutzer Steven E Method and materials for detecting lyme disease
US5217872A (en) 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
WO1991013630A1 (en) 1990-03-05 1991-09-19 The United States Of America, Represented By The Secretary, United States Department Of Commerce ANTIGENIC PROTEINS OF $i(BORRELIA BURGDORFERI)
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
US5155022A (en) 1991-02-08 1992-10-13 Becton, Dickinson And Company Assay for lyme disease
US5283175A (en) 1991-04-15 1994-02-01 The Research Foundation Of State University Of New York Genus-specific oligomers of Borrelia and methods of using same
US5324630A (en) 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US5304718A (en) 1992-02-03 1994-04-19 Research Corporation Technologies, Inc. Cytoplasmic male sterile quinoa
EP0894143B2 (de) 1996-02-21 2012-04-18 Board Of Regents, The University Of Texas System Vmp-ähnliche sequenzen von pathogener borrelia
DE19632862B4 (de) 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
CN1261896A (zh) 1997-06-30 2000-08-02 杜雷安教育基金会行政处 诊断和预防莱姆病用的组合物的表面抗原和蛋白质
US6064586A (en) * 1998-12-31 2000-05-16 Siros Technologies, Inc. Method for holographic data storage and retrieval
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
US6958967B2 (en) * 2000-11-17 2005-10-25 Matsushita Electric Industrial Co., Ltd. Holographic optical information recording/reproducing device
US6862120B2 (en) * 2001-03-22 2005-03-01 Pioneer Corporation Hologram recording medium, hologram recording method and hologram recording and reproducing apparatus

Also Published As

Publication number Publication date
US7785597B2 (en) 2010-08-31
DE69733944D1 (de) 2005-09-15
US8354240B2 (en) 2013-01-15
AU2191597A (en) 1997-09-10
EP1589109B1 (de) 2017-04-12
US6719983B2 (en) 2004-04-13
DK0894143T4 (da) 2012-07-16
US20100317026A1 (en) 2010-12-16
US20030060618A1 (en) 2003-03-27
US20030092903A1 (en) 2003-05-15
US20040214225A1 (en) 2004-10-28
US7135176B2 (en) 2006-11-14
US20160266112A1 (en) 2016-09-15
US20040044192A1 (en) 2004-03-04
US20120122238A1 (en) 2012-05-17
DK0894143T3 (da) 2005-09-19
US8071109B2 (en) 2011-12-06
DE69733944T2 (de) 2006-04-13
EP0894143B1 (de) 2005-08-10
EP0894143A1 (de) 1999-02-03
US9212218B2 (en) 2015-12-15
US20050176947A1 (en) 2005-08-11
US6740744B2 (en) 2004-05-25
EP0894143A4 (de) 2001-06-13
US6437116B1 (en) 2002-08-20
ATE301716T1 (de) 2005-08-15
DE69733944T3 (de) 2012-07-26
US6878816B2 (en) 2005-04-12
EP1589109A3 (de) 2005-11-16
WO1997031123A1 (en) 1997-08-28
US20130245234A1 (en) 2013-09-19
US20070117970A1 (en) 2007-05-24
EP1589109A2 (de) 2005-10-26

Similar Documents

Publication Publication Date Title
US9212218B2 (en) Vmp-like sequences of pathogenic Borrelia
US10759833B2 (en) VMP-like sequences of pathogenic Borrelia species and strains
AU697305B2 (en) Methods and compositions including a 13 kD B. burgdorferi protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/31 A, 7C 07K 14/20 B, 7C 12Q 1/68 B, 7G 01N 33/68 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010503

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030509

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWALTSBUERO JEAN HUNZIKER

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69733944

Country of ref document: DE

Date of ref document: 20050915

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060110

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20060126

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

ET Fr: translation filed
PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: MIKROGEN MOLEKULARBIOLOGISCHE ENTWICKLUNGS-GMBH

Effective date: 20060504

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

NLR1 Nl: opposition has been filed with the epo

Opponent name: MIKROGEN MOLEKULARBIOLOGISCHE ENTWICKLUNGS-GMBH

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070228

RIC2 Information provided on ipc code assigned after grant

Ipc: G01N 33/68 20060101ALI20071221BHEP

Ipc: C12Q 1/68 20060101ALI20071221BHEP

Ipc: C07K 14/20 20060101AFI20071221BHEP

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PLBC Reply to examination report in opposition received

Free format text: ORIGINAL CODE: EPIDOSNORE3

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20120418

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AEN

Free format text: AUFRECHTERHALTUNG DES PATENTES IN GEAENDERTER FORM

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 69733944

Country of ref document: DE

Effective date: 20120418

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R008

Ref document number: 69733944

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R039

Ref document number: 69733944

Country of ref document: DE

Effective date: 20130207

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160222

Year of fee payment: 20

Ref country code: CH

Payment date: 20160211

Year of fee payment: 20

Ref country code: DE

Payment date: 20160216

Year of fee payment: 20

Ref country code: DK

Payment date: 20160210

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20160209

Year of fee payment: 20

Ref country code: SE

Payment date: 20160211

Year of fee payment: 20

Ref country code: GB

Payment date: 20160217

Year of fee payment: 20

Ref country code: BE

Payment date: 20160113

Year of fee payment: 20

Ref country code: NL

Payment date: 20160210

Year of fee payment: 20

Ref country code: FR

Payment date: 20160125

Year of fee payment: 20

Ref country code: AT

Payment date: 20160125

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69733944

Country of ref document: DE

Ref country code: DE

Ref legal event code: R040

Ref document number: 69733944

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69733944

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20170219

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20170220

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20170219

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 301716

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170219